We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,800
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Prevalence of Carbapenemases in *Acinetobacter baumannii*

M.M. Ehlers, J.M. Hughes and M.M. Kock

*University of Pretoria/NHLS
South Africa*

1. Introduction

*Acinetobacter baumannii* (*A. baumannii*) is an important opportunistic pathogen and causes a variety of nosocomial infections especially in Intensive Care Units (ICU’s) (Bergogne-Berezin & Towner, 1996; Villegas & Harstein, 2003). These infections include bacteraemia, surgical-site infections, secondary meningitis, urinary tract infections and ventilator associated pneumonia (Bergogne-Berezin & Towner, 1996; Villegas & Harstein, 2003). *Acinetobacter baumannii* has multiresistant phenotypes, including resistance to broad-spectrum β-lactams, fluoroquinolones, aminoglycosides and carbapenemases and therefore treatment of this pathogen is complicated (Coelho et al., 2004; Dalla-Costa et al., 2003; Jeon et al., 2005; Landman et al., 2002; Naas et al., 2005; Vahaboglu et al., 2006; Zarrilli et al., 2004). The multiresistant phenotypes of *A. baumannii* also contributed to the emergence of multi drug resistant *Acinetobacter baumannii* (MDRAB), which have become more prevalent within the past decade (Coelho et al., 2004) and has also caused an increase in the number of nosocomial infections in the past decade (Joly-Guillou, 2005).

Over the last 20 years, there has been an increase in the interest of the *Acinetobacter* species (Giamarellou et al., 2008). The increase in interest is due to i) worldwide expansion of ICU’s, leading to a change in the types of infections caused by *Acinetobacter spp* and ii) due to the emergence of MDRAB and cases of pan-drug resistant *A. baumannii* (PDRAB) have also been reported (Giamarellou et al., 2008).

The acquired carbapenem resistance in *A. baumannii* is often associated with carbapenemase production; IMP, VIM and SIM-type metallo-β-lactamase production or the OXA-24, OXA-23 and OXA-58 type class D carbapenemases (Brown & Amyes, 2006; Poirel & Nordmann, 2006). Also associated with acquired carbapenem resistance in *A. baumannii* is the over production of natural oxacillinase (OXA-51) (Poiré & Nordmann, 2006).

Carbapenemases are the most versatile of all β-lactamases and many of them recognize almost all hydrolysable β-lactams (Livermore & Woodford, 2006; Nordmann & Poirel 2002; Walther-Rasmussen & Hoiby, 2006). Most carbapenemases are resistant to commercial β-lactamase inhibitors (Livermore & Woodford, 2006; Nordmann & Poirel, 2002; Walther-Rasmussen & Hoiby, 2006). Carbapenemases are divided into three subclasses on the basis of their hydrolysis characteristics (Frere et al., 2005). The first carbapenemases described
were from Gram-positive bacilli and were inhibited by EDTA (Frere et al., 2005). These carbapenemases were described as metalloenzymes and have one zinc atom in the active site (Frere et al., 2005). This zinc atom facilitates hydrolysis of a bicyclic β-lactam ring (Frere et al., 2005). The second form of carbapenemases use serine at the active sites and are inactivated by clavulanic acid and tazobactam (β-lactamase inhibitors) (Rasmussen et al., 1996; Yang et al., 1990). Molecular classes A, C and D have serine in the active site and form part of the β-lactamases (Bush, 1988). The molecular class B of the β-lactamases are metalloenzymes and have zinc in the active site (Bush, 1988). The enzymes from the molecular classes A, B and D have the ability to hydrolyze carbapenems, which results in an elevated carbapenem minimum inhibitory concentration (Bush, 1988).

The aim of this study was to optimise and evaluate multiplex polymerase chain reaction (PCR) assays to rapidly differentiate the four subgroups of the oxacillinase (OXA) genes and the five subgroups of the metallo-β-lactamase (MBL) antibiotic resistant genes. The PCR assays results were compared to the phenotypic tests i) Hodge test and ii) Double disk synergy test. Antibiotic resistance testing is important to decrease the spread of antibiotic resistant strains of *A. baumannii* in clinical settings.

2. History of *Acinetobacter baumannii*

*Acinetobacter baumannii* (Figure 1) was first isolated in 1911 from a soil sample by MW Beijerinck (Kuo et al., 2004). *Acinetobacter spp* were first thought to be non-virulent saprophytes (Bergogne-Berezin & Towner, 1996). In the 1970s the widespread use and misuse of antibiotics started (Kuo et al., 2004). In 1986 *Acinetobacter baumannii* was taxonomically classified (Bouvet et al., 1986). The first carbapenem resistant *A. baumannii* (CRAB) isolates were discovered in 1991 (Kuo et al., 2004). The first carbapenem hydrolyzing oxacillinase (CHDL’s) was identified in 1995 (Scaife et al., 1995). It was initially named ARI-1 and was later renamed OXA-23 (Scaife et al., 1995).

![Fig. 1. *Acinetobacter baumannii* isolates (www.acinetobacter.org)](www.intechopen.com)
The first reported outbreak of CRAB occurred in the USA in 1991 (Go et al., 1994). Carbapenem Resistant *A. baumannii* isolates were isolated from a leukaemia patient in the oncology ward of a Taiwanese hospital in May 1998 (Hsueh et al., 2002). These isolates were observed to be resistant to almost all antibiotics e.g. cephalosporins, aztreonam, aminoglycosides and ciprofloxacin and were therefore named pan-drug resistant *A. baumannii* (PDRAB) (Hsueh et al., 2002). The rise in the number of multi drug resistant *A. baumannii* (MDRAB) strains has been due to the extensive use of antimicrobial chemotherapy against bacterial infections (Hsueh et al., 2002).

### 3. Classification of *Acinetobacter baumannii*

In 1986 *Acinetobacter baumannii* was taxonomically classified (Bouvet et al., 1986). *Acinetobacter* are grouped into three main complexes: i) *Acinetobacter calcoaceticus-baumannii* complex, which is glucose oxidizing and non-haemolytic; ii) *Acinetobacter lwoffii*, which are glucose negative and non-haemolytic and iii) *Acinetobacter haemolyticus*, which is haemolytic (Euzeby, 2008). The full classification of *A. baumannii* is listed in Table 1.

| Domain       | Bacteria                                      |
|--------------|-----------------------------------------------|
| Phylum       | Proteobacteria                                |
| Class        | Gammaproteobacteria                           |
| Order        | Pseudomonadales                               |
| Family       | Moraxellaceae                                 |
| Genus        | Acinetobacter                                 |
| Species      | *A. baumannii*                                |
|              | *A. baylyi*                                   |
|              | *A. beijerinckii*                             |
|              | *A. bouvetii*                                 |
|              | *A. calcoaceticus*                            |
|              | *A. gerneri*                                  |
|              | *A. grimontii*                                |
|              | *A. gyllenbergii*                             |
|              | *A. haemolyticus*                             |
|              | *A. johnsonnii*                               |
|              | *A. junnii*                                   |
|              | *A. lwoffii*                                  |
|              | *A. parvus*                                   |
|              | *A. radioresistens*                           |
|              | *A. schindleri*                               |
|              | *A. soli*                                     |
|              | *A. tandoi*                                   |
|              | *A. tjernbergiae*                             |
|              | *A. towneri*                                  |
|              | *A. ursingii*                                 |
|              | *A. venetianus*                               |
|              | 14 species are still unnamed                  |

Table 1. Nomenclature of *Acinetobacter baumannii* (Euzeby, 2008)
There are 21 recognized genomic species of the genus *Acinetobacter* and 14 unnamed genomic species (Euzeby, 2008).

### 4. General characteristics of *Acinetobacter baumannii*

*Acinetobacter baumannii* are Gram-negative, non-fermentative, non-motile, oxidase-negative, aerobic coccobacilli that are ubiquitous in nature and commonly found within the hospital environment causing a variety of opportunistic nosocomial infections (Bergogne-Berezin et al., 1996). The bacteria can be isolated from water, soil and the environment and from human skin (Bergogne-Berezin et al., 1996). The morphology of *Acinetobacter* spp is variable in Gram-stained human clinical specimens and thus cannot be used to differentiate *Acinetobacter* from other causes of common nosocomial infections (http://microbewiki.kenyon.edu/index.php/Acinetobacter_baumannii). *Acinetobacter baumannii* are non-lactose fermenting bacteria, however they partially ferment lactose on MacConkey agar (http://microbewiki.kenyon.edu/index.php/Acinetobacter_baumannii). All the species of the *Acinetobacter* genus grow well on MacConkey agar (except for *A. lwoffii*), when salt is absent (http://microbewiki.kenyon.edu/index.php/Acinetobacter_baumannii). *Acinetobacter baumannii* are strict aerobes and grow well on nutrient agar (http://microbewiki.kenyon.edu/index.php/Acinetobacter_baumannii). Infection by *A. baumannii* is difficult to combat due to the Gram-negative nature of the cell wall as the outer wall provides a barrier so that the antimicrobial agent is unable to enter the bacterial cell (Projan, 2004).

*Acinetobacter baumannii* is an opportunistic pathogen that is successful in colonizing and persisting in the hospital environment and is able to resist desiccation (Getchell-White et al., 1989; Jawad et al., 1996). The bacterium is also able to survive on inanimate surfaces for months (Kramer et al., 2006). *Acinetobacter baumannii* is among the most common causes of device related nosocomial infections (Dima et al., 2007; Thongpiyapoom et al., 2004), resulting when the bacterium is able to resist both physical and chemical disinfection, by forming a biofilm (Cappelli et al., 2003; Loukili et al., 2006; Pajkos et al., 2004). Biofilm associated proteins (BAP’s) were first characterized in *S. aureus* (Cucarella et al., 2001) and have been found in a number of other Gram-positive and Gram-negative pathogenic bacteria.

#### 4.1 Optimal Growth conditions for *Acinetobacter baumannii*

*Acinetobacter baumannii* form part of the natural flora of the skin and mucous membranes of humans (Seifert et al., 1997). *Acinetobacter baumannii* are ubiquitous in clinical and natural environments and commonly colonises the skin, oropharynx secretions, respiratory secretions, urine, irrigating and intravenous solutions (Seifert et al., 1997). *Acinetobacter baumannii* can be cultured from sputum or respiratory secretions, wound and urine (Go & Cuhna, 1999). The pathogen colonises the gastro-intestinal tract and is associated with nosocomial meningitis, nosocomial pneumonia and bacteraemia (Go & Cuhna, 1999).

*Acinetobacter baumannii* grown on trypticase soy agar produce circular, convex, smooth and slightly opaque colonies, which are 1.5 to 2.0 mm in diameter after 24 hours at 30°C or 3.0 to 4.0 mm after 48 hours (Garrity et al., 2005). *Acinetobacter baumannii* do neither haemolyse horse blood nor sheep blood when grown on blood agar plates (Garrity et al., 2005). Seasonal variations have been reported for nosocomial *A. baumannii* infections and
Prevalence of Carbapenemases in Acinetobacter baumannii

bacteraemia, with increased incidences occurring in the summer months (McDonald et al., 1999).

5. Risk factors for Acinetobacter baumannii infections

Acinetobacter baumannii can survive on various surfaces within hospitals, including catheters and other medical equipment (http://microbewiki.Kenyon.edu/index.php/Acinetobacter_ baumannii). Thus environmental contamination is an important source of infection as pathogens are spread directly from surfaces or through the hands of healthcare workers to patients (Corbella et al., 1996). Infected or colonized patients are important reservoirs of A. baumannii. Acinetobacter baumannii is passed from patient to patient via direct and indirect contact (D’Agata et al., 2000). The main risk factors of Acinetobacter baumannii bacteraemia are invasive procedures e.g. central venous catheterization, mechanical ventilation and surgery (Seifert et al., 1995b). Another major risk factor for A. baumannii infections is the widespread use of broad-spectrum antibiotics (Cisneros & Rodriguez-Bano, 2002). Other risk factors include prolonged hospital stay, ICU stay, enteral feeding, previous administration to another unit and previous use of third generation cephalosporins (Mulin et al., 1995; Scerpella et al., 1995).

The risk factors within the ICU’s concern the immunosuppressed patients, patients previously exposed to antimicrobial therapy, patients who underwent high invasive procedures and patients who suffered from previous sepsis (Garcia-Garmendia et al., 2001). Other risk factors include pneumonia as a source of infection, inappropriate empirical treatment and prior treatment with carbapenems (Robenshtok et al., 2006). Surgical procedures performed within the emergency operating theatre is another major risk factor contributing to the spread of epidemic cases of A. baumannii, however the main risk factor was the previous use of fluoroquinolones (Villers et al., 1998).

5.1 Pathogenesis of Acinetobacter baumannii

Acinetobacter baumannii infections are associated with systems of high fluid content e.g. lungs, cerebrospinal fluid, peritoneal fluid and the urinary tract and usually only occur in the immunocompromised patients (Cuhna, 2007). Patients with A. baumannii bacteraemia usually have signs and symptoms that are related to the organ system involved (Cuhna, 2007). Symptoms include wound infections, outbreaks of nosocomial pneumonia, catheter associated bacteriuria, urethritis and continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis (Cuhna, 2007). Bacteraemia results in septic shock in 25-30% of all cases and disseminated intravascular coagulation frequently occurs (Cisneros et al., 1996; Seifert et al., 1997). Colonisation may occur after an invasive infection (Corbella et al., 1996), especially in burn patients (Wisplinghoff et al., 2004). Problems rarely associated with A. baumannii infections include meningitis, endocarditis, urinary tract infections, pneumonia and cholangitis (Cuhna, 2007). Other problems that rarely occur are soft tissue infections and complicated skin, abdominal infections and central nervous system (CNS) infections (Fournier & Richet, 2006). Allen and Green documented the first report of airborne spread of A. baumannii in 1987. Acinetobacter baumannii survives much better on fingertips or on dry surfaces when tested under stimulated hospital environmental conditions (Jawad et al., 1996). The skin of patients and medical personnel is involved in the transmission of A. baumannii strains and in some outbreaks; molecular typing has identified the epidemic
strain on the skin of the patients (Gerner-Smidt, 1987; Patterson et al., 1991). Contaminated reusable medical equipment e.g. ventilator tubing, respirometers and arterial pressure monitoring devices are used for the management of severely ill patients serve as another route of transmission to patients (Beck-Sague et al., 1990; Cefai et al., 1990). Fomites e.g. bed mattresses (Sheretz & Sullivan, 1985), pillows (Weernink et al., 1995), a tape recorder, television set and a fan (Jawad et al., 1994) were found to be contaminated with *Acinetobacter* and served as reservoirs during nosocomial outbreaks.

The mortality rate within the hospitals is high, with a 23% mortality recorded for hospitalized patients and a 43% mortality rate among patients in intensive care (Falagas et al., 2006). The Antimicrobial Availability Task Force (AATF) of the Infectious Disease Society of America identified *Acinetobacter baumannii, Aspergillus* spp, extended spectrum β-lactamase producing *Enterobacteriaceae, Pseudomonas aeruginosa, Staphylococcus aureus* as “particularly problematic pathogens” and there is a desperate need for new drug development (Talbot et al., 2006).

It is difficult to distinguish between colonization and infection regarding *A. baumannii* (Joly-Guillou, 2005). There is controversy over whether infections caused by *A. baumannii* result in unfavourable outcomes (Blot et al., 2003; Falagas et al., 2006). The isolation of *A. baumannii* in hospitalized patients is an indicator of severe illness with an associated mortality of approximately 30% (Wilson et al., 2004).

Community acquired *A. baumannii* (CAAB) occurs within an individual with one or more cultures of blood, collected within 48 hours of admission, that is positive for *A. baumannii* complex and is identified by a biochemical method (API 20NE system) (bioMerieux, France) (Schreckenberger & Von Graevenitz, 2000). Patients with CAAB associated pneumonia had an increased mortality rate and presented with a more severe disease than the patients without pneumonia (Wang et al., 2002). The development of CAAB is associated with underlying malignancies e.g. lung cancer, lymphoma and thymic carcinoma (Wang et al., 2002). *Acinetobacter baumannii* genomic species were responsible for CAAB; however there is no evidence of clonal spread of *A. baumannii* in the community (Wang et al., 2002). Carbapenems, cefepime, cephalosporins, cefazidime, aminoglycosides and fluoroquinolones are the antimicrobials of choice for treating CAAB (Wang et al., 2002).

### 5.2 Virulence factors of *Acinetobacter baumannii* strains

*Acinetobacter baumannii* have very few virulence factors (Cisneros & Rodriguez-Bano, 2002), however some strains have virulence factors associated with invasiveness, transmissibility or the enhanced ability to colonise immunocompromised patients (Dijkshoorn et al., 1996). Ethanol stimulates the virulence of *A. baumannii* (Smith et al., 2004), which led to the identification of a number of genes, affecting virulence towards *Caenorhabditis elegans* and *Dictyostelium discoideum* (Smith et al., 2007).

A new strain (OXA-23 clone II) was identified in a military hospital and was found to be a particularly virulent strain, which is very difficult to eliminate from medical facilities (promedmail). There are three major European clones of *A. baumannii* (Giamarellou et al., 2008) Clone I, found in South Africa, Czech Republic, Poland, Italy and Spain; Clone II, found in South Africa, Spain, Turkey, Greece and France and clone III is found in the Netherlands, Italy, France and Spain (Van Dessel et al., 2004). Clones I and II are responsible for the outbreaks of
A. baumannii bacteraemia in South Africa and Northern Europe (Van Dessel et al., 2004). Acinetobacter can efficiently transfer genes horizontally (only observed and analysed in A. baylyi), especially the genes encoding antibiotic resistance (Gerischer, 2008).

A large portion of the A. baumannii genome is dedicated to pathogenesis, with a large number of genes occurring within virulence islands (Perez et al., 2007). Acinetobacter baumannii together with Acinetobacter DNA group13TU is involved in the majority of Acinetobacter hospital outbreaks (Bergogne-Berezin & Towner, 1996). Strains of the Acinetobacter DNA group 3 and A. junii have only occasionally been implicated in outbreaks of nosocomial infections (Bernards et al., 1997). Acinetobacter baumannii has environmental resilience and a wide range of resistance determinants, therefore making it a successful nosocomial pathogen (Nordmann, 2004). Acinetobacter baumannii has caused numerous global outbreaks and displayed ever increasing rates of resistance (Villegas & Harstein, 2003). In hospital outbreaks the emergence of imipenem-resistant strains has been documented (Brown et al., 1996; Go et al., 1994).

6. Clinical manifestations of Acinetobacter baumannii infections

The clinical manifestations of A. baumannii are non-specific and present as a trans-maculopapular rash affecting the palms of the hands and the soles of the feet of endocarditis patients, or necrotic lesions of the skin and soft tissue (Seifert et al., 1995). Acinetobacter baumannii bacteraemia is polymicrobial, and is often associated with Klebsiella pneumoniae (Seifert et al., 1995).

6.1 Treatment of Acinetobacter baumannii infections

Acinetobacter baumannii are Gram-negative bacteria and therefore are particularly difficult to treat due to the presence of an outer membrane (Projan, 2004). The recommended treatment therefore is a limited spectrum active β-lactam e.g. ceftazidime or imipenem the most active agent against A. baumannii and an aminoglycoside (Cisneros & Rodriguez-Bano, 2002).

There is incomplete current knowledge of the clinical response and bacterial mechanisms of resistance to antimicrobials (Kahlmeter et al., 2006). The reliability and comparability of different methods of susceptibility testing e.g. disc diffusion and broth microdilution have not been consistent for A. baumannii (Swenson et al., 2004). The persistence of subtle growth beyond an obvious end point by broth microdilution is of great concern in the case of β-lactams, which therefore explains its poor reaction with the disc diffusion method (Swenson et al., 2004). Doripenem, a novel carbapenem is active against susceptible A. baumannii (Fritsche et al., 2005; Jones et al., 2004; Jones et al., 2005; Mushtaq et al., 2004). Doripenem was not effective against A. baumannii isolates producing blaoXA-23 or blaIMP-4 or metallo-β-lactamases (Mushtaq et al., 2004).

6.2 Carbapenems as treatment for Acinetobacter baumannii infections

Carbapenems are structurally related to the penicillins (“penams”), differing only by the substitution of carbon (“carba”) for the sulfur atom at position 1 and the presence of a double bond between C2 and C3 (Bradley, 1997; Wise, 1986). A hydroxyethyl side chain instead of the acylamino group found in penicillins and cephalosporins is present and provides resistance to most β-lactamases (Bradley, 1997; Wise, 1986).
Carbapenems were introduced into clinical practice in the 1970’s and the 1980’s marked the emergence of Gram-negative bacterial resistance to carbapenems (Nordmann & Poirel, 2002; Walsh, 2005). Carbapenems were derived from the naturally occurring antibiotic, thienamycin, which is produced by the soil microorganism *Streptomyces cattleya* (Jacobs, 1986). The first carbapenemases described were from Gram-positive bacilli and were inhibited by EDTA (Frere et al., 2005). Carbapenems are recognised as the gold standard for treating infections caused by resistant Gram-negative bacteria (Rahal, 2006).

### 6.3 Combination therapy as a strategy for the treatment of multiple drug resistant *Acinetobacter baumannii*

Sulbactam is an inhibitor of β-lactamases and has *in vitro* bactericidal activity against *Acinetobacter spp* (Cisneros & Rodriguez-Bano, 2002). The efficacy of sulbactam against susceptible *A. baumannii* is similar to imipenem (Rodriguez-Hernandez, 2000). Sulbactam exhibits bacteriostatic action against *A. baumannii* (Corbella et al., 1998). Sulbactam is also used to treat meningitis caused by multiple drug resistant *Acinetobacter baumannii* (MDRAB) (Cisneros & Rodriguez-Bano, 2002). Combinations of sulbactam with aminoglycosides, rifampin and azithromycin have demonstrated synergy against imipenem susceptible strains (Appleman et al., 2000; Savov et al., 2002). There is little or no advantage to the combination sulbactams with cephalosporins (Appleman et al., 2000; Savov et al., 2002).

Polymyxins (colistimethate and polymyxin B) are the only alternative treatment for sulbactam resistant *A. baumannii* strains (Wood & Reboli, 1993). Colistin was used in the 1960’s and the 1970’s, but had many adverse side effects, including nephrotoxicity, neuro-muscular blockage (Cisneros & Rodriguez-Bano, 2002). Colistin disrupts the outer cell membranes of many Gram-negative bacilli by changing the permeability of the membrane and causing a bactericidal effect (Cisneros & Rodriguez-Bano, 2002). Colistin is only recommended for patients who have no other treatment alternatives (Cisneros & Rodriguez-Bano, 2002). Rifampicin combined with colistin or sulbactam acts synergistically against MDRAB (Hogg et al., 1998).

### 7. Mechanisms of antibiotic resistance in *Acinetobacter baumannii*

The general mechanisms of resistance are enzyme-mediated resistance, genetic adaption, efflux pumps and changes in the structure of outer membrane components (Cloete, 2003). Enzyme mediated resistance is the ability of the bacteria to produce enzymes that transform the antibiotics into non-toxic or inactivated forms (Ma et al., 1998). Efflux pumps involve a large number of seemingly unrelated (structurally) compounds, pumped out of the cell, which lowers the concentration of the drug within the cell and therefore prohibits the drug to take proper effect (Nikaido, 1996). Changes in the structure of the outer membrane and its components e.g. porins and alterations in the penicillin binding proteins (PBP’s), allows for the cells to develop resistance to antimicrobials on the basis of exclusion because the drugs are no longer able to penetrate the cells and therefore the drugs can’t reach their intended site of action in the cell (Cloete, 2003).

*Acinetobacter baumannii* has become resistant to many classes of antibiotics and is well suited for genetic exchange (Lorenz & Wackernagel, 1994; Metzgar et al., 2004). *Acinetobacter baumannii* are among a unique class of Gram-negative bacteria that are described as “naturally transformable” (Lorenz & Wackernagel, 1994; Metzgar et al., 2004). *Acinetobacter*
Prevalence of Carbapenemases in *Acinetobacter baumannii* strains lack the *mut*S gene, which is part of the mismatch repair system that preserves genetic stability and exhibits increased mutation rates (Young & Ornston, 2001). It is unknown whether *A. baumannii* are naturally competent or whether through the alteration of environmental conditions facilitates pathogenicity or antibiotic resistance gene acquisition (Fournier et al., 2006). The key resistance genes identified were those coding for VEB-1, AmpC, and OXA-10 beta-lactamases, various amino glycoside-modifying enzymes (AME) and those genes encoding for the tetracycline efflux pumps (Fournier et al., 2006).

Plasmids, transposons and the bacterial chromosome are involved in antibiotic resistance within *A. baumannii* (Bergogne-Berezin & Towner, 1996). Carbapenemases occurring within *A. baumannii* belong to the class D family of serine-β-lactamases or the imipenemase (IMP)/Verona integrase (VIM) class B family of metallo-β-lactamases (Brown & Amyes, 2006). Imipenem is the most active drug against *A. baumannii* (Cisneros & Rodriguez-Bano, 2002). Resistance to carbapenemases is associated with reduced drug uptake due to porin deficiency and reduced affinity for the drug due to modification of the PBPs by mutations (Clark, 1996).

*Acinetobacter baumannii*'s largest virulence island contains genetic elements, which are homologous to the type IV secretion systems of *Legionella* and *Coxiella burnetti* (Goldstein et al., 1983). Over 25 years ago *A. baumannii* was observed to acquire antimicrobial resistance factors through conjugation of plasmids (Goldstein et al., 1983). Transposons are important in the dissemination of genetic determinants of resistance in *Acinetobacter* spp (Devaud et al., 1982; Palmen & Hellingwerf, 1997) and many of the transposons contain integrons, predominantly from class I. Integrons contain an *int* gene and gene cassettes that can be mobilized to other integrons or to secondary sites in the bacterial genome (Poirel et al., 2005).

A multi drug resistant (MDR) phenotype in *A. baumannii* occurs when integron-born resistance determinants acting against different classes of antibiotics co-exist, giving rise to MDR gene cassettes (Seward, 1999; Yum et al., 2002). Insertion sequences (IS), which promote gene expression, have played an important role in explaining the regulation of resistance (Segal et al., 2005). The IS*Aba1* element found in *A. baumannii* but not in *Enterobacteriaceae* or in *Pseudomonas aeruginosa* (Segal et al., 2005), results in the over expression of Amp C and OXA-51/OXA-69-like beta-lactamases and in decreased levels of susceptibility to ceftazidime and carbapenems (Heritiere et al., 2006).

### 7.1 Oxacillinase (OXA) genes in *Acinetobacter baumannii*

Carbapenemases are classified into four major functional groups (groups 1 to 4) with multiple subgroups of group 2 that are differentiated according to a group specific inhibitor or substrate profiles (Bush et al., 1995). According to this classification scheme carbapenemases are found primarily in group’s 2f and 3 (Nordmann et al., 1993; Yang et al., 1990).

Class D carbapenemases are classified into four subgroups (Vahaboglu et al., 2006). Subgroup 1, the OXA-23 group (including OXA-27 and OXA-49), are the plasmid encoded genes (Vahaboglu et al., 2006). The OXA extended spectrum beta-lactamases are able to hydrolyze extended spectrum cephalosporins (Aubert, 2001; Walther-Rasmussen & Hoiby, 2006). The OXA-23 was the first OXA carbapenemase (OXA β-lactamases that inactivate
carbapenems) within \textit{A. baumannii} obtained from a clinical isolate (Aubert, 2001; Walther-Rasmussen & Hoiby, 2006). The OXA-23 genes originated in \textit{A. radioresistens} (Turton et al., 2005). This plasmid-encoded enzyme was found in 1985 in Scotland before the introduction of carbapenems (Paton et al., 1993). It was initially named “\textit{Acinetobacter} resistant to imipenem” (ARI-1) and has been discovered in Brazil, England, Polynesia, Singapore, Korea and China (Brown & Amyes, 2006; Jeon et al., 2005). Subgroup 2 is the OXA-24 group (including OXA-25, OXA-26 and OXA-40), which is chromosomally encoded (Vahaboglu et al., 2006). The OXA-24 carbapenemase has a crystal structure and therefore suggests a novel catalytic role for Tyr112 and Met223 side chains (Santillana et al., 2007). Subgroup 1 and 2 share 60% identity (Heritier et al., 2005b).

Subgroup 3 consists of OXA-51 and its variants, which are chromosomally encoded (Vahaboglu et al., 2006). The OXA-51/69 expression varies according to the presence of IS\textit{Aba1} (Poirel & Nordmann, 2006). The OXA-51 gene was first detected in Argentina in 2005, within genetically distinct \textit{A. baumannii} isolates (Brown & Amyes, 2005). Subgroup 3 has 56% identity with subgroup 1 and 61 to 62% identity with subgroup 2 (Brown et al., 2005). Subgroup 4 contains OXA-58, which is a plasmid-encoded gene (Vahaboglu et al., 2006) and was first detected in Toulouse (France) in 2003 (Heritier et al., 2005a; Poirel et al., 2005). Subgroup 4 shares less than 50% homology with the other three groups (Poirel et al., 2005). The OXA-58 gene is rapidly disseminating and those isolates, which contain both OXA-51-type and OXA-58 genes, are pandrug-resistant \textit{A. baumannii} (PDRAB) (Coelho et al., 2006). The plasmid borne carbapenemase, OXA-58, was found in France, England, Argentina, Spain, Turkey, Romania, Austria, Greece, Scotland and Kuwait (Coelho et al., 2006; Marque et al., 2005; Pournaras et al., 2006). It is uncertain whether these genes are acquired or occur naturally in \textit{A. baumannii} (Brown & Amyes, 2006). In \textit{A. baumannii} isolates with OXA-51 as the sole carbapenemase, carbapenem resistance was associated with an insertion sequence IS\textit{Aba1} and it is thought that this might be the promoter for the hyper-production of $\beta$-lactamase genes (Turton et al., 2006).

Bacteria producing carbapenemase enzymes have a reduced susceptibility to imipenem (Ambler et al., 1991). However, the minimum inhibitory concentration (MIC) of imipenem can range from mildly elevated to fully resistant (Ambler et al., 1991). Therefore, these $\beta$-lactamases may not be recognised following routine susceptibility testing (Ambler et al., 1991). Beta-lactamases have the ability to hydrolyse carbapenems, resist commercially available $\beta$-lactamase inhibitors and are susceptible to inhibition by metal ion chelators (Lim et al., 1988). The widespread presence of oxacillinases and their division into distinct subgroups, indicates that these enzymes are an essential component of the genetic makeup of \textit{Acinetobacter} spp (Walther-Rasmussen & Hoiby, 2006). The OXA enzymes as emerging carbapenemases are increasingly associated with outbreaks of \textit{A. baumannii containing OXA-40 and OXA-58} in the United States (Hujer et al., 2006; Lolans et al., 2006). The OXA-51/69-like beta-lactamase is a “naturally occurring” chromosomal enzyme in \textit{Acinetobacter baumannii} and has been found in isolates from four continents (Heritier et al., 2005a).

7.2 Metallo-$\beta$-lactamase (MBL) genes in \textit{Acinetobacter baumannii}

Metallo-$\beta$-lactamases form part of the class B $\beta$-lactamases, capable of hydrolyzing carbapenems and other $\beta$-lactam antibiotics except for aztreonam (Walsh et al., 2005; Walsh,
Prevalence of Carbapenemases in *Acinetobacter baumannii* 223 (2005). Class B β-lactamases differ from class A and class D carbapenemases by having a metal ion, zinc, in their active site, which participates in catalysis (Walsh et al., 2005; Walsh, 2005). There are five types of metallo-β-lactamases (MBL’s) that have been identified in *A. baumannii* (Brown & Amyes, 2006). The most common metallo-β-lactamases include “Verona integron-encoded metallo-β-lactamases” (VIM), “Imipenem hydrolyzing β-lactamase” (IMP), “German Imipenemase” (GIM), Seoul imipenemase (SIM) and Sao Paulo metallo-β-lactamases (SPM-1) enzymes, which are located on a variety of integron structures and are incorporated as gene cassettes (Brown & Amyes, 2006). The integration of the integron on the plasmids or transposons allows for facilitated transfer between bacteria (Watanabe et al., 1991).

Imipenem (IMP) metallo-β-lactamases were first described in a *P. aeruginosa* strain found in Japan in 1988 (Watanabe et al., 1991). Metallo-β-lactamases is not the predominant carbapenemases found within *A. baumannii* however the following carbapenemases have been described: IMP-1, IMP-2, IMP-4, IMP-5, IMP-6, and IMP-11 (Walsh et al., 2005; Walsh, 2005). The IMP type MBL’s have stronger carbapenem-hydrolysing activity than the OXA-type-β-lactamases (Laraki et al., 1999). The VIM, IMP, SPM, and GIM genes are found on cassettes in class 1 integrons, although IMP genes have also been found on class 3 integrons (Collis et al., 2002). Watanabe et al. (1991) reported the detection of IMP-1, located on an integron situated on a conjugative plasmid, in *Serratia marcescens* and other *Enterobacteriaceae* in Japan. The imipenem-hydrolyzing β-lactamase has been detected in rare clinical isolates of *Enterobacter cloaca* in Argentina, the USA and France (Nordmann et al., 1993; Pottumarthy et al., 2003; Radice et al., 2004; Rasmussen et al., 1996).

Imipenem hydrolyzing β-lactamase contains the conserved active site motifs S-X-X-K, S-D-N and K-T-G of the class A β-lactamases (Aubron, 2005; Yu et al., 2006). The carbapenemases have conserved cysteine residues at positions 238 and 69 that form a disulfide bridge (Aubron, 2005; Yu et al., 2006). Genes encoding IMP-2 β-lactamases were found on plasmids in *Enterobacter asburiae* isolated from river water in the US and on plasmids from an *E. cloaca* isolated from China (Aubron, 2005; Yu et al., 2006). The disulfide bond is necessary for the hydrolytic activity and is used to stabilize the enzyme structurally (Majiduddin & Palzkill, 2003; Sougakoff et al., 2002). The mechanism of cleavage of the β-lactam ring is different for MBL’s as compared to β-lactamases, however, both gene products still share a unique Nββα fold in the active sites of the enzymes (Ullah et al., 1998). The *bla* IMP is a foreign gene that is introduced from another species of bacteria and *A. baumannii* only retain the gene in environments where there is selective pressure in the form of the presence of imipenem (Takahashi et al., 2000).

Pandrug-resistant *A. baumannii* (PDRAB) are resistant to nearly all the commercially available antibiotics including amikacin, aztreonam, cefepime, ceftazidime, ciprofloxacin, gentamycin, imipenem, meropenem, ofloxacin, ticarcillin-clavulanate and piperacillin-tazobactam (Hsueh et al., 2002). Carbapenem-resistant *A. baumannii* are usually susceptible to ciprofloxacin, ofloxacin, gentamycin or amikacin (Hsueh et al., 2002). Increasing the use of carbapenems and ciprofloxacin has contributed to the development and spread of PDRAB strains (Hsueh et al., 2002).

Verona integron-encoded MBL (VIM-1) was first identified in Italy in 1997 in a *P. aeruginosa* isolate (Lauretta et al., 1999). *Acinetobacter baumannii* containing the VIM-2 gene has been
reported only in Korea (Yum et al., 2002). *Acinetobacter baumannii* isolates producing metallo-\(\beta\)-lactamases from Korea were reported to be incredibly diverse, containing Seoul imipenemase (SIM-1), which is a novel metallo-\(\beta\)-lactamase (Lee et al., 2005).

### 7.3 Non-enzymatic mechanisms of antibiotic resistance

In *A. baumannii* isolates from Madrid the loss of the 22-kDa and 33-kDa outer membrane proteins combined with the production of OXA-24, resulted in resistance to carbapenems (Bou et al., 2000). A homologue of OprD, a 43-kDa protein was identified in *A. baumannii* (Dupont et al., 2005). The 43-kDa protein is a well studied porin, which is frequently associated with imipenem resistance in *P. aeruginosa* (Dupont et al., 2005). Confirming resistance to imipenem and meropenem in *A. baumannii* is the channel formation of CarO, a 29-kDa outer membrane protein (Limansky et al., 2002; Mussi et al., 2005; Siroy et al., 2005). Reduced expression of PBP-2 within isolates from Seville, Spain explained the resistance of *A. baumannii* to carbapenems (Fernandez-Cuenca et al., 2003).

#### 7.3.1 Efflux pumps as mechanisms of resistance in *Acinetobacter baumannii*

Efflux pumps cause resistance against several different classes of antibiotics and mediate the efflux of compounds that are toxic to the bacterial cell, including antibiotics, in a coupled exchange with protons (Poole, 2005). The distinct families of efflux pumps the major facilitator superfamily, the small multidrug resistance superfamily, the multidrug and toxic compound extrusion superfamily and the resistance-nodulation-cell division family are found in various species of bacteria (Poole, 2005). Over expression of the AdeABC efflux pump, which forms part of the resistance-nodulation-cell division family, confers high-level resistance to carbapenems, together with carbapenem-hydrolyzing oxacillinase (Marque et al., 2005). The mechanism, which controls the expression of the efflux pump, functions as a two-step regulator (adeR) and sensor (adeS) system (Marchand et al., 2004). A single point mutation within the adeR and adeS genes results in increased expression and increased efflux (Marchand et al., 2004).

### 8. Resistance of *Acinetobacter baumannii* to various antibiotics

Resistance to aminoglycosides is mediated by aminoglycoside-modifying enzymes (AME’s) (Perez et al., 2007). Examples of such enzymes include aminoglycoside phosphotransferases (aph), aminoglycoside acetyltransferases (acc) and aminoglycoside adenyltransferase (aad) (Perez et al., 2007). *Acinetobacter baumannii* have transposon mediated efflux pumps, which involves tetracyclines A (Tet) and TetB (Guardabassi et al., 2000). Tetracycline A allows for the efflux of tetracycline, while TetB allows for the efflux of both tetracycline and minocycline (Huys et al., 2005). The other mechanism of resistance to the tetracyclines is due to the ribosomal protection protein (Perez et al., 2007). The ribosomal protection protein is encoded by the tetracycline M gene and protects the ribosome from the action of tetracycline, minocycline and doxycycline (Ribera et al., 2003).

Modification in the structure of the DNA gyrase decreases the affinity of the enzyme to quinolones (Seward & Towner, 1998); therefore *A. baumannii* becomes resistant to quinolones (Perez et al., 2007). Modifications of the lipopolysaccharides (LPS’s) in *A. baumannii* cause the bacterium to become resistant to polymyxins (Perez et al., 2007).
9. Spread and control of *Acinetobacter baumannii*

Infection control is critical concerning *A. baumannii* given its ability to cause outbreaks (Boyce & Pittet, 2002; Pittet, 2004). Contact precautions, hand washing and alcohol hand decontamination are rarely applied however are universally encouraged and important (Boyce & Pittet, 2002; Pittet, 2004). However, the applications of meticulous environmental decontamination and aggressive chlorhexidine baths as temporary measures to control outbreaks are the favourable approach (Maragakis et al., 2004; Wilks et al., 2006). However these methods are expensive, labour-intensive and must be clinically proven through trials (Maragakis et al., 2004; Wilks et al., 2006). The key to infection control measures lies within preventing dissemination of MDR clones (Maragakis et al., 2004; Wilks et al., 2006). The use of molecular tools for investigation of outbreaks to establish clonality among isolates allows for a more effective implementation of infection control measures and aids in the identification of environmental sources (Maragakis et al., 2004; Wilks et al., 2006). Polymerase Chain Reaction followed by electrospray ionization mass spectrometry and base composition analysis are used to determine clonality (Ecker et al., 2006; Hujer et al., 2006). Restriction of the use of especially broad-spectrum activity antibiotics is necessary for infection control strategies (Chakravarti et al., 2000; Hughes, 2003). The refinement of genomic and proteomic techniques represents hope for the discovery of new antimicrobials active against MDR organisms and for the development of vaccines (Chakravarti et al., 2000; Hughes, 2003). The success of these and other approaches for the containment of MDR *A. baumannii* depends on the commitment of clinical practitioners, scientists, hospitals and public health administrators and on the support of the informed public (Chakravarti et al., 2000; Hughes, 2003).

10. Diagnosis and detection of *Acinetobacter baumannii*

Monitoring the geographical spread of virulent or epidemic pathogens is achieved through the identification and typing of bacteria (Grundmann et al., 1997). Traditional methods for the identification of *A. baumannii* are unsatisfactory (Gerner-Smidt et al., 1991), due to the difficulty in distinguishing *A. baumannii* from *A. calcoaceticus* phenotypically (Giamarellou et al., 2008). *Acinetobacter baumannii* is predominantly diagnosed from sputum, blood, central venous catheter tips, pleural fluid, wound pus, bronchial washing and urine (Hsueh et al., 2002).

10.1 Direct phenotypic detection of *Acinetobacter baumannii*

Phenotypic methods of detecting *A. baumannii* include growing the isolates on fluorescein-lactose-denitrification media (FLN) in order to determine the amount of acid produced by the metabolism of glucose (http://microbewiki.kenyon.edu/index.php/Acinetobacter_baumannii). This method is used to differentiate the respective species within the *Acinetobacter* genus (http://microbewiki.kenyon.edu/index.php/Acinetobacter_baumannii). Crude enzyme extracts and β-lactamase activity assays are other phenotypic methods used to
Antibiotic Resistant Bacteria – A Continuous Challenge in the New Millennium

detect antibiotic resistant strains of *A. baumannii* (Takahashi et al., 2000). Biochemical tests used to differentiate *A. baumannii* from other species of the *Acinetobacter* genus include the following: haemolysis test (−), histamine assimilation test (−), glucose oxidation test, citrate assimilation test (+), gelatin liquefaction test (−) (Prashanth & Badrinath, 2000).

10.1.1 Automated detection of *Acinetobacter baumannii*

A Vitek GNI card (bio Mérieux, France) is used for the detection of carbapenemase activity in clinical isolates. The results of the Vitek test are confirmed using the API 20NE system (bio Mérieux, France) (Clinical and Laboratory Standards Institute, 2009).

10.1.2 Manual methods of detection of *Acinetobacter baumannii*

The E-test (AB Biodisk, Sweden) is used to identify metallo-β-lactamase production by determining the minimum inhibitory concentration (MIC), which allows for the detection of the production of VIM or IMP enzymes (Walsh, 2005). Susceptibility testing can be performed using broth microdilution according to Clinical and Laboratory Standards Institute standards (2009) and the Kirby-Bauer double disk synergy test (Peleg et al., 2005). The disk approximation test with 2-mercaptoethanol acid or EDTA is used to screen for metallo-β-lactamase producers (Arakawa, 2000; Yong et al., 2006). Ethylenediaminetetraacetic acid (EDTA) is a chelator of Zn$^{2+}$ and other divalent cations and therefore inhibits the metallo-β-lactamases that have zinc ions in their active sites (Lim et al., 1988).

The imipenem (IMP)-EDTA double-disk synergy test (DDST) can distinguish metallo-β-lactamase producing from metallo-β-lactamase non-producing Gram-negative bacilli (Lee et al., 2001). However, occasional isolates show false negative results due to a deficiency of zinc within the isolate’s active site (Yigit et al., 2001). The test can be improved by using an IMP disk to which 10 µl of 50 mM zinc sulfate (140 µg/disk) has been added, to compensate for the lack of zinc or by using Mueller-Hinton agar to which zinc sulfate has been added to a final concentration of 70 µg.ml$^{-1}$ (Yigit et al., 2001).

The Hodge test is a simple method for screening metallo-β-lactamase producing isolates of Gram-negative bacilli (Lee et al., 2001). The Hodge test/cloverleaf test is a microbiological assay of carbapenemase activity, where an extract of the whole cell or the suspected isolates are tested against imipenem on an agar plate (Hornstein et al., 1997). It is unnecessary to test an isolate for a carbapenemase using the modified Hodge test when all of the carbapenems that are reported by a laboratory test are either intermediate or resistant (Clinical and Laboratory Standards Institute, 2009). However, the modified Hodge test is used for infection control and epidemiological purposes (Clinical and Laboratory Standards Institute, 2009). The imipenem disk test is a poor screening method for carbapenemases (Clinical and Laboratory Standards Institute, 2009).

10.2 Molecular detection of *Acinetobacter baumannii*

Molecular methods based on PCR for the detection of carbapenemase producing genes are used due to the problems with the direct phenotypic detection methods e.g. difficulty in distinguishing between species of the *Acinetobacter* genus (Vaneechoutte, 1996). The molecular methods include a PCR with primers for detecting OXA-23, OXA-24, OXA-51,
Prevalence of Carbapenemases in Acinetobacter baumannii

OXA-58, IMP-1, IMP-2, IMP-4, VIM-1, VIM-2, SPM-1, GIM-1, and SIM-1 genes can be used to detect all families and subgroups of the presumed carbapenemases (Petropoulou et al., 2006). The genotypic tests used to determine the clonal relatedness of the isolates include, Random amplified polymorphism DNA (RAPD PCR)-fingerprinting with the primers M13, Enterobacterial Repetitive Intergenic Consensus (ERIC2) and Pulsed Field Gel Electrophoresis (PFGE) using the Apal enzyme can be performed (Seifert et al., 2005). The main advantages of the molecular techniques in comparison with the traditional phenotypic methods are high reproducibility and applicability to a wide variety of bacteria and time saving (Grundmann et al., 1997).

10.3 Indirect diagnosis of Acinetobacter baumannii

Gram-negative bacteria contain lipopolysaccharides (LPS’s) on their outer membranes, which consist of covalently linked lipid A (anchors the LPS into the outer membrane) and the core polysaccharide (O-polysaccharide or O-antigen), which is linked to the lipid A (Pantophlet et al., 1999). The type of LPS found within A. baumannii has the smooth or S-form phenotype and can be used in clinical microbiology laboratories for clinical research purposes (Pantophlet et al., 1999).

11. Materials and methods

Ninety-seven imipenem/meropenem resistant A. baumannii isolates were collected between March and April 2009 from a Tertiary Academic hospital. These isolates were all given a unique number. The A. baumannii isolates were analysed by the Diagnostic Division of the department of Medical Microbiology, National Health Laboratory service (NHLS) at the University of Pretoria. The isolates were identified as A. baumannii and underwent susceptibility testing. The Vitek 2 (bioMérieux, France) automated system was used to phenotypically test for the presence of carbapenemases within the A. baumannii isolates. Ninety-seven imipenem/meropenem resistant isolates were streaked out onto 5% sheep blood agar plates (Diagnostics Media Products, NHLS, South Africa). The plates were incubated (Horo incubator) overnight at 37°C. Gram-staining was performed for each isolate. (2002). Brain-Heart infusion broth (Biolab, Wadeville, South Africa) was prepared and aliquoted into Bijou culture bottles before sterilization. The broth bottles were inoculated from overnight plate cultures of A. baumannii grown on 5% sheep blood agar (Diagnostic Media Products, NHLS, South Africa) by adding 3 to 4 colonies of an isolate into the broth. The inoculated broths were incubated in a Labcon shake incubator at 37°C overnight. A volume of 900 μl of the inoculated turbid broth and 900 μl of sterile glycerol was added to a sterilized cryotube and were stored at -70°C. The CLSI (2009) guidelines for the performance of the modified Hodge test and for the double disk synergy test were followed for the detection of carbapenemase production.

A MagNA Pure Compact Nucleic Acid Isolation Kit 1 (Roche, Germany) was used to perform automated whole cell DNA extraction according to the manufacturer’s guidelines. A volume of 400 μl of each of the A. baumannii broth culture samples was added to a Magna Pure sample tube for automated DNA extraction. Sealed cartridges with the necessary reagents were added to each lane. The purified nucleic acids (100 μl of pure A. baumannii
DNA) were eluted and stored at -20°C for further analysis. The Nanodrop Spectrophotometer ND-1000 instrument was used to measure the DNA concentration for each of the samples.

Two multiplex PCR assays: 1) Multiplex PCR I reaction of OXA-23, OXA-24, OXA-51 and OXA-58 genes (Woodford et al., 2006) and 2) Multiplex PCR II reaction of IMP, VIM, GIM-1, SPM-1 and SIM-1 genes (Ellington et al., 2007) were performed using the QIAGEN Multiplex PCR 1000 kit (Promega, Madison, USA), which was set up according to the manufacturer’s guidelines. The QIAGEN Multiplex PCR 1000 kit contains Multiplex PCR Master mix, RNAse free water and Q solution. The thermocycling was performed using the Eppendorf, Mastercycler epgradient S (Hamburg, Germany). The DNA gel electrophoresis (Elite 300 power pack, Wealtec, South Africa) was performed on a 2% agarose gel (Whitehead Scientific, Brackenfell, Cape Town), which contained 0.5 µg.ml⁻¹ ethidium bromide (Promega, Madison, USA). The loading dye used was Fermentas 6X orange loading dye solution (Fermentas UAB, Lithuania). The ready to use 100 bp ladder (Promega, Madison, USA) was used as a molecular size marker. A 10% solution of TBE buffer 10X (Promega, Madison, USA) was used for the preparation and running of the gels.

12. Prevalence of antibiotic resistance genes in Acinetobacter baumannii isolates in a clinical setting in the Pretoria area, South Africa

The origins of the Acinetobacter baumannii isolates collected in this study were 58% (56/97) from sputum specimens, 7% (7/97) from urine specimens, 11% (11/97) from blood cultures and 24% (23/97) from diverse specimens. The A. baumannii isolates collected for this study were both imipenem and meropenem resistant with a minimum inhibitory concentration (MIC) of >=16. The 97 A. baumannii isolates were subjected to susceptibility testing using the Vitek 2 instrument. The panel consisted of 18 antibiotics to determine the overall pattern of resistance. The selection of A. baumannii isolates used in this study was based on the Vitek 2 instrument. Both imipenem and meropenem resistant A. baumannii isolates were included in this study. All of the A. baumannii isolates showed 100% resistance to the following antibiotics in the panel: ampicillin; amoxicillin/clavulanic acid; cefuroxime; cefuroxime axetil; cefepime; imipenem; meropenem; nitrofurantoin and trimethoprim/sulfamethoxazole. The A. baumannii clinical isolates were all susceptible (0% resistance) to colistin (Table 2).

The Hodge test showed that 74% (72/97) of the A. baumannii isolates were positive for carbapenemase production and 26% (25/97) of the A. baumannii isolates were negative for carbapenemase production (Figure 2). These results are similar to the findings of the study conducted in Korea by Lee et al. (2003), which reported a prevalence of 66% positive for carbapenemase production, 26% negative for carbapenemase production and 8% data unknown.

The Cloverleaf or Hodge test is cumbersome and imperfect. False positives occur due to AmpC and impermeability, not due to β-lactamase production. Weak false positives occur due to AmpC hyperproducers. AmpC hydrolysing β-lactams are produced by Gram-negative bacteria [Presentation by David Livermore on “Detecting carbapenemases” at the 49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC)]. Some A. baumannii isolates are resistant to ertapenem, but are rarely resistant to any of the other
| Antibiotic Tested                  | Percentage resistance |
|-----------------------------------|-----------------------|
| Ampicillin                        | 100% (97/97)          |
| Amoxicillin/Clavulanic acid       | 100% (97/97)          |
| Piperacillin/Tazobactam           | 99% (96/97)           |
| Cefuroxime                        | 100% (97/97)          |
| Cefuroxime Axetil                 | 100% (97/97)          |
| Cefotaxime                        | 99% (96/97)           |
| Ceftazidime                       | 49% (48/97)           |
| Cefepime                          | 100% (97/97)          |
| Imipenem                          | 100% (97/97)          |
| Meropenem                         | 100% (97/97)          |
| Amikacin                          | 25% (24/97)           |
| Gentamicin                        | 89% (86/97)           |
| Tobramycin                        | 5% (5/97)             |
| Nalidixic acid                    | 95% (92/97)           |
| Ciprofloxacin                     | 91% (88/97)           |
| Nitrofurantoin                    | 100% (97/97)          |
| Colistin                          | 0% (0/97)             |
| Trimethoprim/sulfamethoxazole     | 100% (97/97)          |

Table 2. Antibiotic resistance patterns in *Acinetobacter baumannii* isolates from a Tertiary Academic Hospital

Fig. 2. Hodge or cloverleaf test of three *Acinetobacter baumannii* isolates
carbapenems. The Hodge test is very time consuming to set up and the reading of the results is subjective. Some strains produce bacteriocins, which kill the indicator organism [Presentation by David Livermore on “Detecting carbapenemases” at the 49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC)]. Beta-lactamase production affects the porins of the outer membrane, thus making \( A.\ baumannii \) impermeable to antibiotics and therefore resistant to antibiotics e.g. carbapenems [Presentation by David Livermore on “Detecting carbapenemases” at the 49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC)]. The class of carbapenemase cannot be determined by the results of the Modified Hodge test. Some isolates show a slight indentation, but do not produce carbapenemase (Standard operating procedure of the Department of Health and Human Services, Centers for Disease Control and Prevention: “Modified Hodge Test for Carbapenemase Detection in Enterobacteriaceae”).

The double disk synergy test showed that 33\% (32/97) of the \( A.\ baumannii \) isolates were susceptible to both ertapenem and EDTA and 19\% (18/97) of the isolates did not grow (Figure 3). A prevalence of 45\% (44/97) was recorded for \( A.\ baumannii \) isolates that were ertapenem resistant and EDTA susceptible and a prevalence of 3\% (3/97) was recorded for both ertapenem and EDTA resistance. These findings are lower than the results of the study conducted in Korea by Lee et al. (2003), which reported a prevalence of 94\% (75/80) of \( A.\ baumannii \) isolates susceptible for both imipenem and EDTA; all the isolates grew in that study; 5\% (5/97) of the \( A.\ baumannii \) isolates were resistant to imipenem and susceptible to EDTA and 0\% (0/97) isolates were resistant to both imipenem and EDTA.

Fig. 3. Double disk synergy test of one \textit{Acinetobacter baumannii} isolate

EDTA permeabilizes the bacterial cell, is a chelator of zinc and disrupts OXA dimers, which may be stabilized by zinc [Presentation by David Livermore on “Detecting carbapenemases”].
Prevalence of Carbapenemases in *Acinetobacter baumannii* at the 49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC). Therefore EDTA disrupts the function of the carbapenemase producing genes and hence the *A. baumannii* isolates are more susceptible to ertapenem in the presence of EDTA than without EDTA. The discrepancies in the results of this study compared to the results of the study conducted by Lee et al. (2003) were due to the use of different carbapenems. Ertapenem was used in this study, while Lee et al. used imipenem in their study conducted in 2003. Imipenem disks perform poorly as a screen for carbapenemases (Clinical and Laboratory Standards Institute, 2009) and thus ertapenem was used in this study.

The *A. baumannii* clinical specimens were cultured and two different multiplex PCR assays were performed on the extracted DNA sample of each isolate. The first multiplex PCR assay (Multiplex PCR I) was performed to screen for the presence of the OXA-group genes (OXA-23, OXA-24, OXA-51 and OXA-58). The second Multiplex PCR assay (Multiplex PCR II) screened for the presence of the Metallo-β-lactamase genes (IMP, VIM, SIM, SPM and GIM). Multiplex PCR I showed that 80% (78/97) of the *A. baumannii* isolates were positive for OXA-51, 52% (50/97) were positive for OXA-23, 1% (1/97) were positive for OXA-58 and 2% (2/97) were positive for OXA-24 (Figure 4). Figure 5 showed the gel electrophoresis pattern of the OXA-51, OXA-23, OXA-58 and OXA-24 genes.

![Pie chart showing the results of the Multiplex PCR I for the prevalence of the OXA genes in the 97 *Acinetobacter baumannii* isolates obtained from a Tertiary Academic Hospital](image-url)

Fig. 4. Pie chart showing the results of the Multiplex PCR I for the prevalence of the OXA genes in the 97 *Acinetobacter baumannii* isolates obtained from a Tertiary Academic Hospital.
Fig. 5. Results obtained after Multiplex PCR I was performed, using a 2% agarose gel for the detection of OXA genes in the *Acinetobacter baumannii* isolates. Lanes 2, 3, 4, 5, 7, 9, 10, 11, 12 and 13 were positive for both OXA-51 and OXA-23. Lane 6 was positive only for OXA-51. Lane 8 was positive for OXA-23, OXA-51 and OXA-58. Lanes 1 and 14 contain the molecular weight markers (100 bp DNA ladder).

The multiplex PCR I results showed there were four distinctive strains of *A. baumannii* circulating in a Tertiary Academic hospital in Gauteng, South Africa. The first group of strains were positive for both OXA-51 and OXA-23 (52%). The second group of strains was positive for OXA-51 (26%) alone. The third group of strains were positive for both OXA-51 and OXA-24 (2%) and the fourth group of strains were positive for both OXA-51 and OXA-58 (1%) (Figure 6).

Fig. 6. Pie chart showing the results of the Multiplex PCR I for the four strains of *Acinetobacter baumannii* circulating in a Tertiary Academic Hospital
OXA-51 is an ubiquitous or naturally occurring gene within *A. baumannii* (Merkier & Centron, 2006). OXA-51 is a chromosomally located gene, which needs to be regulated upstream by IS_{Aba1} to provide resistance [Presentation by David Livermore on “Detecting carbapenemases” at the 49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC)]. The prevalence of OXA-51 in clinical isolates of *A. baumannii* in this study was 80% (78/97). This figure is lower than the findings of a study conducted in Iran by Feizabadi and colleagues (2008), which reported a 100% prevalence of the OXA-51 gene in clinical isolates of *A. baumannii*.

The prevalence of OXA-23 in clinical isolates of *A. baumannii* in this study was 52% (50/97). This finding was similar to the OXA-23 prevalence of 66.5% in the Asia Pacific nations (India, China, Thailand, Singapore, Hong kong and Korea) (Mendes et al., 2009). However, based on other studies conducted in Iran by Feizabadi and colleagues (2008) who reported a prevalence of 36.5% in clinical isolates of *A. baumannii* the prevalence of OXA-23 varies worldwide. OXA-23 forms part of the class D metallo-β-lactamases and is an acquired carbapenemase gene, thus a varied prevalence is observed as not all *A. baumannii* isolates will contain the gene compared to OXA-51 which is a chromosomal carbapenemase gene occurring naturally in *A. baumannii* (Merkier & Centron, 2006). The carbapenemase gene occurs in widespread clones and contributes to the multidrug resistant nature of *A. baumannii* [Presentation by David Livermore on “Detecting carbapenemases” at the 49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC)].

The OXA-24 genes also form part of the class D metallo-β-lactamases and are acquired carbapenemase genes, which occur within widespread clones [Presentation by David Livermore on “Detecting carbapenemases” at the 49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC)]. The prevalence of OXA-24 in *A. baumannii* in this study was 2% (2/97). This finding was similar to the OXA-24 prevalence of 5.6% in *A. baumannii* clinical isolates from a study conducted in Thailand, Taiwan and Indonesia in 2008 (Mendes et al., 2008). However, a prevalence of 26% of OXA-24 was reported in the study conducted by Feizabadi and colleagues in Iran in 2008. The varied prevalence results are due to OXA-24 being an acquired gene within *A. baumannii* and thus not all isolates will contain the gene (Merkier & Centron, 2006).

The prevalence of OXA-58 in clinical isolates of *A. baumannii* in this study was 1% (1/97). This finding was lower than the OXA-58 prevalence of 15% in *A. baumannii* isolates in the study conducted by Feizabadi and colleagues in Iran in 2008. The differences in the results of this study and other studies are due to OXA-58 being an acquired carbapenemase gene and the presence of this gene within widespread clones Presentation by David Livermore on “Detecting carbapenemases” at the 49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC)].

No metallo-β-lactamase genes were detected in any of the *A. baumannii* isolates. IMP, VIM, SIM, SPM and GIM genes belong to the class B metallo-β-lactamases and are acquired carbapenemase genes. IMP (primarily detected in South Korea) and VIM (previously detected in China) are the two metallo-β-lactamase genes, which are the most frequently detected genes in *A. baumannii* isolates (Coelho et al., 2006). The prevalence of the metallo-β-lactamase genes is generally low within *A. baumannii* isolates as illustrated in a study by Mendes and colleagues (2009) where the prevalence was 0.8% in Taiwan. VIM, SIM, SPM, IMP and GIM have not been
detected in South Africa yet. Therefore the results of this study compared with the literature in that the selected *A. baumannii* isolates were negative for all metallo-β-lactamase genes.

13. Conclusions

Acinetobacter baumannii is an important opportunistic pathogen and causes a variety of nosocomial infections especially within the ICU of the Tertiary Academic Hospital in Gauteng, South Africa. The results of the phenotypic analysis in the form of the Hodge test and Double disk synergy test were similar to the results obtained from the study conducted by Lee et al. in Korea in 2003. The discrepancies with the results of the two studies can be largely due to the use of different carbapenem antibiotic disks. The Hodge test is imperfect as false positives occur due to AmpC production and impermeability of the bacterium to antibiotics due to β-lactamase ability to affect the porins of the outer membrane.

After completion of this study it is evident that the OXA group of genes (class D carbapenemases) are a problem in clinical isolates of *A. baumannii* from the Tertiary Academic Hospital. It was found that OXA-51 genes (80%) and OXA-23 genes (52%) were highly prevalent in this study and these prevalence rates were similar to the worldwide prevalence of OXA genes, which are widespread in *A. baumannii* throughout the world (Feizabadi et al., 2008). Metallo-β-lactamase (MBL) genes were not prevalent in the selected clinical isolates of *A. baumannii* due to the contained spread of the genes and thus no metallo-β-lactamase has been detected in South Africa thus far. According to Livermore molecular tests are definitive, but a few isolates with strong carbapenemase activity were negative in all molecular tests [Presentation by David Livermore on “Detecting carbapenemases” at the 49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC)].

The multiplex PCR assays proved to be a rapid technique for antimicrobial susceptibility testing, however, there is much work to be done in order to investigate the possibilities of multiplex PCR assays as an alternative to current antimicrobial susceptibility testing. Continuous research and surveillance is necessary to monitor the prevalence of antibiotic resistance genes associated with *A. baumannii* in clinical settings. The ability of *A. baumannii* to grow in biofilms poses a threat concerning the possibilities of the spread of both the bacteria and the antibiotic resistance genes, which should be investigated in future research.

14. References

Allen KD & Green HT (1987) Hospital outbreak of multi-resistant Acinetobacter anitratus: an airborne mode of spread? *Journal of Hospital Infections* 9:110-119

Ambler R P, Coulson A F W, Frere J M, Ghuyse J M, Joris B, Forsman M, Levesque R C, Tiraby G & Waley S G (1991) A standard numbering scheme for the class A -β-lactamases. *Biochemistry Journal* 276:269–270

Appleman MD, Belzberg H, Citron DM, Heseltine PN, Yellin AE, Murray J & Berne TV (2000) In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. *Antimicrobial Agents and Chemotherapy* 44:1035–1040

Arakawa Y, Shibata N, Shibayama K, Kurokawa H, Yagi T, Fujiwara H & Goto M (2000) Convenient test for screening metallo-β-lactamase-producing gram-negative bacteria by using thiol compounds. *Journal of Clinical Microbiology* 38:40–43
Prevalence of Carbapenemases in Acinetobacter baumannii

Aubert D, Poirel L, Chevalier J, Leotard S, Pages JM & Nordmann P (2001) Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 45:1615–1620

Aubron C, Poirel L, Ash RJ & Nordmann P (2005) Carbapenemase-producing Enterobacteriaceae, U.S rivers. Emerging Infectious Diseases 11:260–264

Beck-Sagué CM, Jarvis WR, Brook JH, Culver DH, Potts A, Gay E, Shotts BW, Hill B, Anderson RL & Weinstein MP (1990) Epidemic bacteremia due to Acinetobacter baumannii in five intensive care units. American Journal of Epidemiology 132: 723-733

Bergogne-Berezin E & KJ Towner (1996) Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clinical Microbiology Reviews 9:148–165

Bernards AT, Beauford AJ, Dijkshoorn L and van Boven CPA (1997) Outbreak of septicemia in neonates caused by Acinetobacter junii investigated by amplified ribosomal DNA restriction analysis (ARDRA) and four typing methods. Journal of Hospital Infections 35: 129-140

Blot S, Vandewoude K & Colardyn F (2003) Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Medicine 29:471–475

Bou G, Cervero G, Dominguez MA, Quereda C & Martinez-Beltran J (2000) Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. Journal of Clinical Microbiology 38:3299–3305

Bouvet PJM & Grimont PAD (1986) Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., Acinetobacter junii sp. nov. & emended description of Acinetobacter calcoaceticus and Acinetobacter lwoffii. International Journal of Systematic Bacteriology 36: 228-240

Boyce JM & Pittet D (2002) Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infection Control and Hospital Epidemiology 23:S3–40

Bradley JS (1997) Meropenem: A new, extremely broad-spectrum beta-lactam antibiotic for serious infections in pediatrics. The Pediatric Infectious Disease Journal 16:263-268

Brown S, Bantar C, Young H & Amyes S (1996) An outbreak of imipenem resistance in Acinetobacter strains from Buenos Aires, Argentina, abstract C-122, p 56 In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC

Brown S & Amyes SG (2005) The sequences of seven class D β-lactamases isolated from carbapenem-resistant Acinetobacter baumannii from four continents. Clinical Microbiology and Infectious Diseases 11:326-329

Brown S, Young HK & Amyes SG (2005) Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clinical Microbiology and Infectious Diseases 11: 15-23

Brown S & Amyes S (2006) OXA-β-lactamases in Acinetobacter: the story so far. Journal of Antimicrobial Chemotherapy 57:1-3

www.intechopen.com
Bush K (1988) Recent developments in lactamase research and their implications for the future. *Reviews of Infectious Diseases* 10:681–690; 739–743

Bush K, Jacoby GA & Medeiros AA (1995) A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrobial Agents and Chemotherapy* 39:1211-1233

Cappelli G, Sereni L, Scialoja MG, Morselli M, Perrone S, Ciuffreda A, Bellesia M, Inguaggiato P, Albertazzi A & Tetta C (2003) Effects of biofilm formation on haemodialysis monitor disinfection. *Nephrology Dialysis Transplantation* 18:2105–2111.

Cefai C, Richards J, Gould FK & McPeake P (1990) An outbreak of *Acinetobacter* respiratory tract infection resulting from incomplete disinfection of ventilatory equipment. *Journal of Hospital Infections* 15: 177-182

Chakravarti DN, Fiske MJ, Fletcher LD, & Zagursky RJ (2000) Application of genomics and proteomics for identification of bacterial gene products as potential vaccine candidates. *Vaccine* 19:601–612

Cisneros JM, Reyes MJ & Pachón J (1996) Bacteremia due to *Acinetobacter baumannii*: epidemiology, clinical and prognostic features. *Clinical Infectious Diseases* 22: 1026-1032

Cisneros JM & Rodriguez-Bano J (2002) Nosocomial bacteremia due to *Acinetobacter baumannii*: epidemiology, clinical features and treatment. *Clinical Microbiology and Infection* 8: 687-693

Clark RB (1996) Imipenem resistance among *Acinetobacter baumannii*: association with reduced expression of a 33-36-kDa outer membrane protein. *Journal of Antimicrobial Chemotherapy* 38: 245-51

Clinical and Laboratory Standards Institute (2009) Performance standards for antimicrobial susceptibility testing, Nineteenth informal supplement. CLSI document M100-S-19. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania

Cloete TE (2003) Resistance mechanisms of bacteria to antimicrobial compounds. *International Biodeterioration and Biodegradation* 51: 277-282

Coelho J, Woodford N, Turton J & Livermore DM (2004) Multiresistant *Acinetobacter* in the UK: how big a threat? *Journal of Hospital Infections* 58:167–169

Coelho J, Woodford N, Afzal-Shah M & Livermore D (2006) Occurrence of OXA-58-like carbapenemases in *Acinetobacter* spp. collected over 10 years in three continents. *Antimicrobial Agents and Chemotherapy* 50:756–758

Collis CM, Kim JM, Stokes HW & Hall RM (2002) Integron-encoded Intl integrases preferentially recognize the adjacent cognate attl site in recombination with a 59-be site. *Molecular Microbiology* 46: 1415-1427

Corbella X, Pujol M & Ayats J (1996) Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant *Acinetobacter baumannii*. *Clinical Infectious Diseases* 23:329-334

Corbella X, Ariza J, Ardanuy C, Vueltia M, Yubau F, Sora M, Pujol M & Gudiol F (1998) Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant *Acinetobacter baumannii*. *Clinical Infectious Diseases* 24:793-802

Cucarella C, Solano C, Valle J, Amorena B, Lasa I & Penades JR (2001) Bap, a *Staphylococcus aureus* surface protein involved in biofilm formation. *Journal of Bacteriology* 183:2888–2896

Cuhna BA. *Acinetobacter* (2007) http://www.emedicine.com/MED/topic3456.htm
Prevalence of Carbapenemases in *Acinetobacter baumannii* 237

Dalla-Costa LM, Coelho JM, Souza HAPHM, Castro MES, Stier CJN, Bragagnolo KL, Reaneto A, Pentead-Filho SR, Livermore DM & Woodford N (2003) Outbreak of carbapenem-resistant *Acinetobacter baumannii* producing the OXA-23 enzyme in Curitiba, Brazil. *Journal of Clinical Microbiology* 41:3403–3406

D’Agata EMC, Thayer V & Schaffner W (2000) An outbreak of *Acinetobacter baumannii*: the importance of cross-transmission. *Infection Control of Hospital Epidemiology* 21: 588-591

Devaud M, Kayser FH & Bach B (1982) Transposon-mediated multiple antibiotic resistance in *Acinetobacter* strains. *Antimicrobial Agents and Chemotherapy* 22:323–329

Dijkshoorn L, Aucken HM, Gerner-Smidt P, Janssen P, Kaufmann ME, Garaizar J, Ursing J & Pitt TL (1996) Comparison of outbreak and non-outbreak *Acinetobacter baumannii* strains by genotypic and phenotypic methods. *Journal of Clinical Microbiology* 34: 1519-1525

Dima S, Kritsotakis EI, Roumbelaki M, Metalidis S, Karabinis A, Maguina N, Klouva F, Levidiotou S, Zakynthinos E, Kioumis J & Gika A (2007) Device-associated nosocomial infection rates in intensive care units in Greece. *Infection Control and Hospital Epidemiology* 28:602-605

Dupont M, Pages JM, Lafitte D, Siroy A & Bollet C (2005) Identification of an OprD homologue in *Acinetobacter baumannii*. *Journal of Proteome Research* 4:2386–2390

Ecker JA, Massire C, Hall TA, Ranken R, Pennella TT, Ivy CA, Blyn LB, Hofstadler SA, Endy TP, Scott PT, Lindler L, Hamilton T, Gaddy C, Snow K, Pe M, Fishbain J, Craft D, Deye G, Riddell S, Milstrey E, Petruccelli B, Brisse S, Harpin V, Schink A, Ecker DJ, Sampath R & Eshoo MW (2006) Identification of *Acinetobacter* species and genotyping of *Acinetobacter baumannii* by multilocus PCR and mass spectrometry. *Journal of Clinical Microbiology* 44:2921–2932

Ellington MJ, Kistler J, Livermore DM and Woodford N (2007) Multiplex PCR for rapid detection of genes encoding acquired metallo-β-lactamases. *Journal of Antimicrobial Chemotherapy* 59: 321-322

Euzéby JP (2008) List of prokaryotic names with standing in nomenclature http://www.bacterio.cict.fr/classificationac.html#Acinetobacter

Falagas ME, Bliziotis IA, & Siempos II (2006) Attributable mortality of *Acinetobacter baumannii* infections in critically ill patients: a systematic review of matched cohort and case-control studies. *Critical Care* 10:R48

Feizabadi MM, Fathollahazadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, AligholiM, Soroush S & Mohammadie-Yegane S (2008) Antimicrobial susceptibility patterns and distribution of *blaOXA* genes among *Acinetobacter* spp isolated from patients at Tehran hospitals. *Japanese Journal of Infectious Diseases* 61: 274-278

Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC, Ayala CA, Perea EJ & Pascual A (2003) Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of *Acinetobacter baumannii*. *Journal of Antimicrobial Chemotherapy* 51:565–574

Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, Richet H, Robert C, Mangenot S, Abergel C, Nordmann P, Weissenbach J, Raoult D & Claverie JM (2006) Comparative genomics of multidrug resistance in *Acinetobacter baumannii*. *PLoS Genetics*. 2e7

Frere JM, Galleni M, Bush K & Dideberg O (2005) Is it necessary to change the classification of lactamases? *Journal of Antimicrobial Chemotherapy* 55:1051-1053

www.intechopen.com
Fritsche TR, Stilwell MG, and Jones RN (2005) Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). *Clinical Microbiology and Infections* 11:974–984

Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez FJ, Perez-Paredes C, Barrero-Almodovar AE & Gili-Miner M (2001) Risk factors for *Acinetobacter baumannii* nosocomial bacteremia in critically ill patients: a cohort study. *Clinical Infectious Diseases* 33:939–946

Garrity GM, Brenner DJ, Krieg RN & Staley JT (2005) *Bergey’s Manual of Systematic Bacteriology*, Volume 2: The Proteobacteria, Part B: The Gammaproteobacteria, pg 415-435. Springer, New York, USA

Gerischer U (2008) *Acinetobacter Molecular Biology* 1st edition, Caister Academic Press ISBN 987-1-904455-20-2

Gerner-Smidt P (1987) Endemic occurrence of *Acinetobacter calcoaceticus* biovar anitratus in an intensive care unit. *Journal of Hospital Infections* 10: 265-272

Gerner-Smidt P, Tjernberg I & Usring J (1991) Reliability of phenotypic tests for identification of *Acinetobacter species*. *Journal of Clinical Microbiology* 29: 277-282

Getchell-White SI; Donowitz LG & Groeschel DHM (1989) The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: evidence for long survival of *Acinetobacter calcoaceticus*. *Infection Control and Hospital Epidemiology* 10: 402-407

Giamarelou H, Antoniadou A & Kanellakopoulou (2008) Review: *Acinetobacter baumannii*: a universal threat to public health? *International Journal of Antimicrobial Agents* 32: 106-119

Go ES, Urban C, Burns J, Kreiswirth B, Eisner W & Mariano NF (1994) Clinical and molecular epidemiology of *Acinetobacter* infections sensitive only to polymyxin B and sulbactam. *Lancet* 12:1329-1332

Go J and Cuhna BA (1999) *Acinetobacter baumannii*: Infection control implications. *Infectious Disease Practices* 23: 65-68

Goldstein FW, Labigne-Roussel A, Gerbaud G, Carlier C, Collatz E & Courvalin P (1983) Transferable plasmid-mediated antibiotic resistance in *Acinetobacter*. *Plasmid* 10:138–147

Grundmann HJ, Towner KJ, Dijkshoorn L, Gerner-Smidt P, Maher M, Seifert H & Vaneechoutte M (1997) Multicenter study using standardized protocols and reagents for evaluation of reproducibility of PCR-based fingerprinting of *Acinetobacter spp*. *Journal of Clinical Microbiology* 35: 3071-3077

Guardabassi L, Dijkshoorn L, Collard JM, Olsen JE & Dalsgaard A (2000) Distribution and *in vitro* transfer of tetracycline resistance determinants in clinical and aquatic *Acinetobacter* strains. *Journal of Medical Microbiology* 49: 929-936

Heritier C, Duboux A, Poirel L, Marty N & Nordmann P (2005a) A nosocomial outbreak of *Acinetobacter baumannii* isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58. *Journal of Antimicrobial Chemotherapy* 55: 115-118

Heritier C, Poirel L, Fournier, Claverie J, Raoult D & Nordmann P (2005b) Characterization of the naturally occurring oxacillinase of *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy* 49: 4174-4179

Heritier C, Poirel L & Nordmann P (2006) Cephalosporinase overexpression resulting from insertion of ISAba1 in *Acinetobacter baumannii*. *Clinical Microbiology and Infection* 12:123–130
Prevalence of Carbapenemases in *Acinetobacter baumannii*

Hogg GM, Barr JG & Webb CH (1998) *In-vitro* activity of the combination of colistin and rifampicin against multidrug-resistant strains of *Acinetobacter baumannii*. *Journal of Antimicrobial Chemotherapy* 41: 494-495

Hornstein M, Sautteau-Rostoker C, Peduzzi J, Vessieres A, Hong LT, Barthelemy M, Scaviazi M & Labia R (1997) Oxacillin-hydrolyzing lactamase involved in resistance to imipenem in *Acinetobacter baumannii*. *FEMS Microbiology Letters* 153:333–339

Hsueh P-R, Teng L-J, Chen C-Y, Chen W-H, Yu C-J, Ho S-W & Luh K-T (2002) Pandrug-Resistant *Acinetobacter baumannii* causing nosocomial infections in a University in Taiwan. *Emerging Infectious Diseases* 8: 827-832

Hughes D (2003) Exploiting genomics, genetics and chemistry to combat antibiotic resistance. *Nature Reviews Genetics* 4:432–441

Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CJ, Ecker DJ, Massire C, Eshoo MW, Sampath R, Thomson JM, Rather PN, Craft DW, Fishbain JT, Ewell AJ, Jacobs MR, Paterson DL & Bonomo RA (2006) Analysis of antibiotic resistance genes in multidrug-resistant *Acinetobacter* sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. *Antimicrobial Agents and Chemotherapy* 50:4114–4123

Huys G, Cnockaert M, Vaneechoutte M, Woodford N, Nemec A, Dijkshoorn L & Swings J (2005) Distribution of tetracycline resistance genes in genotypically related and unrelated multiresistant *Acinetobacter baumannii* strains from different European hospitals. *Research in Microbiology* 156: 348-355

Jacobs RF: *Imipenem-cilastatin* (1986) The first thienamycin antibiotic *The Pediatric Infectious Disease Journal* 5:444-448

Jawad A, Hawkey PM, Herritage J & Snelling AM (1994) Description of Leeds *Acinetobacter* Medium, a new selective and differential medium for isolation of clinically important *Acinetobacter* spp and comparison with Herellea agar and Holton’s agar. *Journal of Clinical Microbiology*. 32: 2353-2358

Jawad A, Heritage J, Snelling AM, Gascoyne-Binzi DM & Hawkey PM (1996) Influence of relative humidity and suspending menstrual on survival of *Acinetobacter* spp on dry surfaces. *Journal of Clinical Microbiology* 34: 2881-2887

Jeon B, Jeong SH, Bae IK, Kwon SB, Lee K, Young D, Lee JH, Song JS & Lee SH (2005) Investigation of a nosocomial outbreak of imipenem-resistant *Acinetobacter baumannii* producing the OXA-23-lactamase in Korea. *Journal of Clinical Microbiology* 43:2241–2245

Joly-Guillou ML (2005) Clinical impact and pathogenicity of *Acinetobacter*. *Clinical Microbiology and Infection* 11:868–873

Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR & Sader HS (2004) Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. *Journal of Antimicrobial Chemotherapy* 54:144–154

Jones RN, Sader HS & Fritsche TR (2005) Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. *Diagnostic Microbiology and Infectious Disease* 52:71–74

Kahlmeter G., Brown DF, Goldstein FW, MacGowan AP, Mouton JW, Odenholt I, Rodloff A, Soussy CJ, Steinbakk M, Soriano F & Stetsiouk O (2006) European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing. *Clinical Microbiology and Infection* 12:501–503

www.intechopen.com
Kramer A, Schwebke I & Kampf G (2006) How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. *BMC Infectious Diseases* 6:130

Kuo L, Teng L, Yu C, Ho S and Hsueh P (2004) Dissemination of a clone of unusual phenotype of pandrug-resistant *Acinetobacter baumannii* at a University Hospital in Taiwan. *Journal of Clinical Microbiology* 42: 1759-1763

Landman D, Quale J M, Mayorga D, Adedeji A, Vangala K, Ravishankar J, Flores C & Brooks S (2002) Citywide clonal outbreak of multiresistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in Brooklyn, NY: the preantibiotic era has returned. *Archives of Internal Medicine* 162:1515–1520

Laraki N, Franceschini N, Rossolini GM, Santucci P, Meunier C, de Pauw, Amicosante G, Frère JM & Galleni (1999) Biochemical characterization of the *Pseudomonas aeruginosa* 101/1477 metallo-β-lactamase IMP-1 produced by *Escherichia coli*. *Antimicrobial Agents and Chemotherapy* 43: 902-906

Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R & Rossolini GM (1999) Cloning and characterization of *bla*VIM, a new integron-borne metallo-lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. *Antimicrobial Agents and Chemotherapy* 43:1584– 1590

Lee K, Chong Y, Shin HB, Kim YA, Yong D & Yum JH (2001) Modified Hodge test and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of *Pseudomonas* and *Acinetobacter* species. *Clinical Microbiology and Infection* 7:88-91

Lee K, Lee WG, Uh Y, Ha GY, Cho J, Chong Y & the Korean Nationwide Surveillance of Antimicrobial Resistance group (2003) VIM- and IMP-Type Metallo-β-lactamase-Producing *Pseudomonas* spp. and *Acinetobacter* spp. in Korean Hospitals. *Emerging Infectious Diseases* 9: 868–871

Lee K, Yum JH, Yong D, Lee HM, Kim HD, Docquier JD, Rossolini GM & ChongY (2005) Novel acquired metallo-beta-lactamase gene, *blaSIM-1*, in a class 1 integron from *Acinetobacter baumannii* clinical isolates from Korea. *Antimicrobial Agents and Chemotherapy* 49:4485–4491

Lim HM, Pene JJ & Shaw RW (1988) Cloning, nucleotide sequence, and expression of the *Bacillus cereus* 5/B/6-lactamase II structural gene. *Journal of Bacteriology* 170:2873–2878

Limansky AS, Mussi MA & Viale AM (2002) Loss of a 29-kilodalton outer membrane protein in *Acinetobacter baumannii* is associated with imipenem resistance. *Journal of Clinical Microbiology* 40:4776–4778

Livermore DM & Woodford N (2006) The lactamase threat in *Enterobacteriaceae*, *Pseudomonas* and *Acinetobacter*. *Trends in Microbiology* 14:413–420

Lolans K, Rice TW, Munoz-Price LS & Quinn JP (2006) Multicity outbreak of carbapenem-resistant *Acinetobacter baumannii* isolates producing the carbapenemase OXA-40. *Antimicrobial Agents and Chemotherapy* 50:2941– 2945

Loukili NH, Granbastien B, Faure K, Guery B, and Beaucaire G (2006) Effect of different stabilized preparations of peracetic acid on biofilm. *Journal of Hospital Infections* 63:70-72

Lorenz MG & Wackernagel W (1994) Bacterial gene transfer by natural genetic transformation in the environment. *Microbiological Reviews* 58:563– 602

Ma JF, Hager PW, Howell ML, Phibbs PV & Hasset D (1998) Cloning and characterization of *Pseudomonas aeruginosa* zwf gene encoding glucose-6-phosphate dehydrogenase, an enzyme important in resistance to methyl viologen (paraquat). *Journal of Bacteriology* 180: 1741-1749

www.intechopen.com
Majiduddin FK & Palzkill T (2003) Amino acid sequence requirements at residues 69 and 238 for the SME-1-lactamase to confer resistance to lactam antibiotics. *Antimicrobial Agents and Chemotherapy* 47:1062–1067

Maragakis LL, Cosgrove SE, Song X, Kim D, Rosenbaum P, Ciesla N, Srinivasan A, Ross T, Carroll K & Perl TM (2004) An outbreak of multidrug-resistant *Acinetobacter baumannii* associated with pulsatile lavage wound treatment. *Journal of the American Medical Association* 292:3006–3011

Marchand I, Damier-Piolle L, Courvalin P & Lambert T (2004) Expression of the RND-type efflux pump AdeABC in *Acinetobacter baumannii* is regulated by the AdeRS two-component system. *Antimicrobial Agents and Chemotherapy* 48:3298–3304

Marque S, Poirel L, Heritier C, Brisse S, Blasco MD, Filip R, Coman G, Naas T & Nordmann P (2005) Regional occurrence of plasmid mediated carbapenem-hydrolyzing oxacillinase OXA-58 in *Acinetobacter* spp. in Europe. *Journal of Clinical Microbiology* 43:4885–4888

McDonald LC, Banerjee SN, Jarvis WR & the National Nosocomial Infections Surveillance System (1999) Seasonal variation of *Acinetobacter* infections: 1987-96. *Clinical Infectious Diseases* 29:1133-1137

Mendes RE, Bacher JM, Turnidge JD, Castanheira M & Jones RN (2009) Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among *Acinetobacter* spp in Asia-Pacific nations: report from the SENTRY Surveillance Program. *Journal of Antimicrobial Chemotherapy* 63:55-59

Merkier AK & Centron D (2006) *blaOXA-51*-type β-lactamase genes are ubiquitous and vary within a strain in *Acinetobacter baumannii*. *International Journal of Antimicrobial Agents* 28:110-113

Metzgar D, Bacher JM, Pezo V, Reader J, Doring V, Schimmel P, Marliere P & de Crecy-Lagard V (2004) *Acinetobacter* sp. ADP1: an ideal model organism for genetic analysis and genome engineering. *Nucleic Acids Research* 32:5780–5790

Mulin B, Talon D & Viel JF (1995) Risk factor for nosocomial colonization with multiresistant *Acinetobacter baumannii*. *European Journal of Clinical Microbiology and Infectious Diseases* 14:569-576

Mushtaq S, Ge Y & Livermore DM (2004) Comparative activities of doripenem versus isolates, mutants, and transconjugants of *Enterobacteriaceae* and *Acinetobacter* spp. with characterized beta-lactamases. *Antimicrobial Agents and Chemotherapy* 48:1313–1319

Mussi MA, Limansky AS & Viale AM (2005) Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of *Acinetobacter baumannii*: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. *Antimicrobial Agents and Chemotherapy* 49:1432–1440

Naas T, Levy M, Hirschauer C, Marchandin H & Nordmann P (2005) Outbreak of carbapenem-resistant *Acinetobacter baumannii* producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. *Journal of Clinical Microbiology* 43:4826–4829

Nikaido H (1996) Multidrug efflux pumps of Gram-negative bacteria. *Journal of Bacteriology* 178: 5853-5859

Nordmann P, Mariotte S, Naas T, Labia R & Nicolas M-H (1993) Biochemical properties of a carbapenem-hydrolyzing-lactamase for *Enterobacter cloacae* and cloning of the gene into *Escherichia coli*. *Antimicrobial Agents and Chemotherapy* 37:939-946
Nordmann, P & Poirel L (2002) Emerging carbapenemases in Gram negative aerobes. *Clinical Microbiology and Infection* 8:321–331

Nordmann, P (2004) *Acinetobacter baumannii*, the nosocomial pathogen par excellence. *Pathologie Biologie* 52:301–303

Pajkos A, Vickery K & Cossart Y (2004) Is biofilm accumulation on endoscope tubing a contributor to the failure of cleaning and decontamination? *Journal of Hospital Infections* 58:224–229

Palmen R & Hellingwerf KJ (1997) Uptake and processing of DNA by *Acinetobacter calcoaceticus* – a review. *Gene* 192:179–190

Pantophlet R, Brade L & Brade H (1999) Identification of *Acinetobacter baumannii* strains with monoclonal antibodies against the O antigens of their lipopolysaccharides. *Clinical and Diagnostic Laboratory Immunology* 6: 323-329

Paton R, Miles RS and Hood J (1993) ARI-1: β-lactamase mediated imipenem resistance in *Acinetobacter baumannii*. *International Journal of Antimicrobial Agents* 2: 81-88

Patterson JE, Vecchio J, Pintelick EL, Farrel P, Mazon D, Zervos MJ & Heirholzer WJ Jr (1991) Association of contaminated gloves with transmission of *Acinetobacter calcoaceticus var anitratus* in an intensive care unit. *American Journal of Medicine* 91: 479-483

Peleg AY, Franklin C, Bell J & Spielman DW (2005) Dissemination of the metallo-β-lactamase gene *blaIMP-4* amongst Gram negative pathogens in a clinical setting in Australia. *Clinical Infectious Diseases* 41:1549-1556

Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN & Bonomo RA (2007) Minireview: Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy* 51: 3471-3484

Peterson AA, Fesik SW & McGroarty EJ (1987) Decreased binding of antibiotics to lipopolysaccharides from polymyxin-resistant strains of *Escherichia coli* and *Salmonella typhimurium*. *Antimicrobial Agents and Chemotherapy* 31: 230-237

Petropoulou D, Tzanetou K, Syriopoulou VP, Daikos GL, Ganteris G & Malamou-Lada E (2006) Evaluation of imipenem/imipenem EDTA disk method for detection of metallo-lactamase-producing *Klebsiella pneumoniae* isolated from blood cultures. *Microbial Drug Resistance* 12:39–43

Pittet D (2004) The Lowbury lecture: behaviour in infection control. *Journal of Hospital Infection* 58:1–13

Poirel L, Cabanne L, Vahaboglu H. & Nordmann P (2005) Genetic environment and expression of the extended-spectrum Beta-lactamase *blaOXA-58* gene in gram-negative bacteria. *Antimicrobial Agents and Chemotherapy* 49:1708–1713

Poirel L & Nordmann P (2006) Carbapenem resistance in *Acinetobacter baumannii*: mechanisms and epidemiology. *Clinical Microbiology and Infection* 12:826–836

Poole K (2005) Efflux-mediated antimicrobial resistance. *Journal of Antimicrobial Chemotherapy* 56:20-51

Pottumarthy S, Moland ES, Jeretschko S, Swanzy SR, Thomson KS and Fritsche TR (2003) NmcA carbapenem-hydrolyzing enzyme in *Enterobacter cloacae* in North America. *Emerging Infectious Diseases* 9:999–1002

Pournaras S, Markogiannakis A, Ikonomidis A, Kondyli L, Bethimouti K, Maniatis AN, Legakis NJ & Tsakris A (2006) Outbreak of multiple clones of imipenem-resistant *Acinetobacter baumannii* isolates expressing OXA-58 carbapenemase in an intensive care unit. *Journal of Antimicrobial Chemotherapy* 57:557-561
Prevalence of Carbapenemases in Acinetobacter baumannii

Prashanth K & Badrinath S (2000) Simplified phenotypic tests for identification of Acinetobacter spp and their antimicrobial susceptibility status. Journal of Medical Microbiology 49: 773-778

Projan SJ (2004) Small molecules for small minds? The case for biologic pharmaceuticals. Expert Opinion on Biological Therapy 4: 1345-1350

Radice M, Power P, Gutkind G, Fernandez K, Vay C, Famiglietti A, Ricover N & Ayala J (2004) First class A carbapenemase isolated from Enterobacteriaceae in Argentina. Antimicrobial Agents and Chemotherapy 48:1068– 1069

Rahal J (2006) Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clinical Infectious Diseases 43: 95-99

Rasmussen B A, Bush K, Keeney D, Yang Y, Hare R, O’Gara C & Medeiros A A (1996) Characterization of IMI-1 β-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrobial Agents and Chemotherapy 40:2080–2086

Ribera A, Ruiz J & Vila J (2003) Presence of the Tet M determinant in a clinical isolate of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 47: 2310-2312

Robenshtok E, Paul M, Leibovici L, Fraser A, Pitlik S, Ostfeld I, Samra Z, Perez S, Lev B & Weinberger M (2006) The significance of Acinetobacter baumannii bacteremia compared with Klebsiella pneumoniae bacteremia: risk factors and outcomes. Journal of Hospital Infection 64: 282-287

Rodriguez-Hernández MJ, Pachón J & Pichardo C (2000) Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. Journal of Antimicrobial Chemotherapy 45: 493-501

Santillana E, Beceiro A, Bou G & Romero A (2007) Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proceedings of the National Academy of Science USA 104:5354–5359

Savov E, Chankova D, Vatcheva R & Dinev N (2002) In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sulbactam alone and in combination with amikacin. International Journal of Antimicrobial Agents 20:390–392

Scaife W, Young HK, Paton RH & Amyes SG (1995) Transferable imipenem-resistance in Acinetobacter species from a clinical source. Journal of Clinical Microbiology 36: 585-586

Scerpella EG, Wanger AR, Armitige L, Anderlini P and Ericsson CD (1995) Nosocomial outbreak caused by a multiresistant clone of Acinetobacter baumannii: results of the case control and molecular epidemiologic investigations. Infection Control and Hospital Epidemiology 16: 92-97

Schreckenberger PC & Von Graevenitz A (2000) Acinetobacter, Achromobacter, Acaligenes, Moraxella, Methyllobacterium and other non-fermentative Gram-negative rods, pg 539-560. In Murray PR, Baron EJ, Pfaller MA, Tenover FC and Yolken RH (ed), Manual of clinical Microbiology, 7th ed. ASM Press, Washington DC, USA

Seifert H, Strate A & Pulverer G (1995) Nosocomial bacteremia due to Acinetobacter baumannii, clinical features, epidemiology and predictors of mortality. Medicine 74: 340-349

Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I & Vaneechoutte A (1997) Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. Journal of Clinical Microbiology 35: 2819-2825
Antibiotic Resistant Bacteria – A Continuous Challenge in the New Millennium

Seifert H, Dolzani L & Bressan R (2005) Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. Journal of Clinical Microbiology 43:4328-35

Segal H, Garny S & Elisha BG (2005) Is IS (ABA-1) customized for Acinetobacter. FEMS Microbiology Letters 243:425-429

Seward, R. J (1999) Detection of integrons in worldwide nosocomial isolates of Acinetobacter spp. Clinical Microbiology and Infection 5:308–318

Seward RJ & Towner KJ (1998) Molecular epidemiology of quinolone resistance in Acinetobacter spp. Clinical Microbiology and Infection 4: 248-254

Sheretz RJ & Sullivan ML (1985) An outbreak of infections with Acinetobacter calcoaceticus in burn patients: contamination of patients’ mattresses. Journal of Infectious Diseases 151: 252-258

Siroy A, Molle V, Lemaitre-Guillier C, Vallenet D, Pestel-Caron M, Cozzone AJ, Jouenne T & De E (2005) Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 49:4876–4883

Smith MG, Des Etages SG & Snyder M (2004) Microbial synergy via an ethanol-triggered pathway. Molecular and Cellular Biology 24:3874–3884

Smith MG, Gianoulis TA, Pukatzki S, Mekalanos JJ, Ornston LN, Gerstein M & Snyder M (2007) New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis. Genes and Development 21:601–614

Sougakoff W, L’Hermite G, Pernot L, Naas T, Guillet V, Nordmann P, Jarlier V & Delettre J (2002) Structure of the imipenem-hydrolyzing class A-lactamase SME-1 from Serratia marcescens. Acta Crystallographica Section D Biological Crystallography Journal 58:267–274

Swenson JM, Killgore GE & Tenover FC (2004) Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods. Journal of Clinical Microbiology 42:5102–5108

Takahashi A, Yomoda S, Kobayashi I, Okubo T, Tsunoda M & Iyobe S (2000) Detection of carbapenemase-producing Acinetobacter baumannii in a hospital. Journal of Clinical Microbiology 38: 526-529

Turton JF, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, & Bartlett JG (2006) Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clinical Infectious Disease 42:657–668

Thongpiyapoom S, Narong MN, Suwalak N, Jamulitrat S, Intaraksa P, Boonrat J, Kasatpibal N & Unahalekhaka A (2004) Device-associated infections and patterns of antimicrobial resistance in a medical-surgical intensive care unit in a university hospital in Thailand. Journal of the Medical Association of Thailand 87:819–824

Turton JF, Kaufmann ME, Glover J, Coelho JM, Warner M, Pike R & Pitt TL (2005) Detection and typing of integrons in epidemic strains of Acinetobacter baumannii found in the United Kingdom. Journal of Clinical Microbiology 43:3074–3082

Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME & Pitt TL. (2006) Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. Journal of Clinical Microbiology 44: 2974-2976
Prevalence of Carbapenemases in *Acinetobacter baumannii*

Ullah JH, Walsh TR, Taylor IA, Emery DC, Verma CS & Gamblin SJ (1998) The crystal structure of the L1 metallo-β-lactamase from *Stenotrophomonas maltophilia* at 1.7 resolution. *Journal of Molecular Biology* 284: 125-136

Vahaboglu H, Budak F, Kasap M, Gacar G, Torol S, Karadenizli A, Kolayli F & Eroglu C (2006) High prevalence of OXA-51-type class D Beta-lactamases among ceftazidime-resistant clinical isolates of *Acinetobacter* spp.: co-existence with OXA-58 in multiple centers. *Journal of Antimicrobial Chemotherapy* 58:537-542

Van Dessel H, Dijkshoorn L, Van der Reijden T, Bakker N, Pauw A & Van de Broek E (2004) Identification of a new geographically widespread multiresistant *Acinetobacter baumannii* clone from European hospitals. *Research in Microbiology* 155: 105-112

Vanechouitte M (1996) DNA fingerprinting techniques for microorganisms. A proposal for classification and nomenclature. *Molecular Biotechnology* 6: 115-142

Villegas MV & Hartstein AI (2003) *Acinetobacter* outbreaks, 1977-2000. *Infection Control and Hospital Epidemiology* 24:284-295

Villers D, Espaze E, Coste-burel M, Giauffret F, Ninin E, Nicolas F & Richet H (1998) Nosocomial *Acinetobacter baumannii* infections: Microbiological and clinical epidemiology. *Annals of Internal Medicine* 129: 182-189

Walsh T, Toleman M, Poirel L & Nordmann P (2005) Metallo-β-lactamases: the quiet before the storm? *Clinical Microbiological Reviews* 18:306-325

Walsh TR (2005) The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria. *Clinical Microbiology and Infection* 11(Suppl. 6):2–9.

Walther-Rasmussen J & Hoiby N (2006) OXA-type carbapenemases. *Journal of Antimicrobial Chemotherapy* 57:373–383

Wang JT, McDonald LC, Chang SC & Ho M (2002) Community-Acquired *Acinetobacter baumannii* bacteremia in adult patients in Taiwan. *Journal of Clinical Microbiology* 40: 1526-1529

Watanabe M, Iyobe S, Inoue M & Mitsuhashi S (1991) Transferable imipenem resistance in *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy* 35:147–151

Weernink A, Severin WPJ, Tjernberg I & Dijkshoorn L (1995) Pillows an unexpected source of *Acinetobacter*. *Journal of Hospital Infections* 29: 189-199

Wilks M, Wilson A, Warwick S, Price E, Kennedy D, Ely A & Millar MR (2006) Control of an outbreak of multidrug-resistant *Acinetobacter baumannii-calcoaceticus* colonization and infection in an intensive care unit (ICU) without closing the ICU or placing patients in isolation. *Infection Control and Hospital Epidemiology* 27:654–658

Wilson SJ, Knipe CJ, Zieger MJ, Gabezahrt KM, Goodman JE, Volk HM & Sood R (2004) Direct costs of multidrug-resistant *Acinetobacter baumannii* in the burn unit of a public teaching hospital. *American Journal of Infection Control* 32:342–344

Wise R (1986) In vitro and Pharmacokinetic properties of the carbapenems. *Antimicrobial Agents and Chemotherapy* 30:343-349

Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP & Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide surveillance study. *Clinical Infectious Diseases* 39: 309-317

Wood CA & Reboli AC (1993) Infections caused by carbapenem-resistant *Acinetobacter calcoaceticus* biotype anatraus. *Journal of Infectious Diseases* 167: 448-451

www.intechopen.com
Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, Amyes SGB & Livermore DM (2006) Multiplex PCR for genes encoding prevalent OXA carbenemases in *Acinetobacter* spp. *International Journal of Antimicrobial Agents* 27: 351-353

Yang Y, Wu P & Livermore D M (1990) Biochemical characterization of a lactamase that hydrolyzes penems and carbapenems from two *Serratia marcescens* isolates. *Antimicrobial Agents and Chemotherapy* 34:755–758

Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K & Tenover F C (2001) Novel carbenem-hydrolyzing-lactamase, KPC-1, from a carbenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrobial Agents and Chemotherapy* 45:1151– 1161

Yong D, Choi YS, Roh KH, Kim CK, Park YH, Yum JH, Lee K and Chong Y (2006) Increasing prevalence and diversity of metallo-β-lactamases in *Pseudomonas* spp., *Acinetobacter* spp., and *Enterobacteriaceae* from Korea. *Antimicrobial Agents and Chemotherapy* 50:1884–1886

Young DM. & Ornston LN (2001) Functions of the mismatch repair gene *mutS* from *Acinetobacter* sp. strain ADP1. *Journal of Bacteriology* 183: 6822–6831

Yu Y-S, Du X-X, Zhou Z-H, Chen Y-G & Li L-J (2006) First isolation of *bla*IMI-2 in an *Enterobacter cloacae* clinical isolate from China. *Antimicrobial Agents and Chemotherapy* 50:1610–1611

Yum JH, Yi K, Lee H, Yong D, Lee K, Kim JM, Rossolini GM & Chong Y (2002) Molecular characterization of metallo-beta-lactamase-producing *Acinetobacter baumannii* and *Acinetobacter* genomospecies 3 from Korea: identification of two new integrons carrying the *bla*VIM-2 gene cassettes. *Journal of Antimicrobial Chemotherapy* 49:837–840.

Zarrilli R, Crispino M, Bagattini M, Barretta E, Popolo A. D, Triassi M & Villari P (2004) Molecular epidemiology of sequential outbreaks of *Acinetobacter baumannii* in an intensive care unit shows the emergence of carbenem resistance. *Journal of Clinical Microbiology* 42:946–953
Antibiotic-resistant bacterial strains remain a major global threat, despite the prevention, diagnosis and antibiotherapy, which have improved considerably. In this thematic issue, the scientists present their results of accomplished studies, in order to provide an updated overview of scientific information and also, to exchange views on new strategies for interventions in antibiotic-resistant bacterial strains cases and outbreaks. As a consequence, the recently developed techniques in this field will contribute to a considerable progress in medical research.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

M.M. Ehlers, J.M. Hughes and M.M. Kock (2012). Prevalence of Carbapenemases in Acinetobacter baumannii, Antibiotic Resistant Bacteria - A Continuous Challenge in the New Millennium, Dr. Marina Pana (Ed.), ISBN: 978-953-51-0472-8, InTech, Available from: http://www.intechopen.com/books/antibiotic-resistant-bacteria-a-continuous-challenge-in-the-new-millennium/antibiotic-resistance-genes-in-acinetobacter-baumannii-isolates

InTech Europe
University Campus STEP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821
